[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5779
1. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D: Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther; 2010 Jan;18(1):161-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
  • As expected, the shRNAs silenced hepatic p53 and accelerated liver tumorigenesis when MYC was concurrently expressed.
  • In MYC-expressing transgenic mice, the marginal shRNA-induced liver injury sufficed to further stimulate hepatocellular division that was in turn associated with markedly increased expression of the mitotic cyclin B1.
  • Hence, even at low doses, shRNAs can cause low-level hepatoxicity that can facilitate the ability of the MYC oncogene to induce liver tumorigenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / chemically induced. Genes, myc / physiology. Liver Neoplasms, Experimental / chemically induced. RNA, Small Interfering / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Gene Ther. 2001 Aug;8(16):1248-54 [11509958.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6487-93 [11522645.001]
  • [Cites] Adv Cancer Res. 2002;84:81-154 [11885563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Semin Liver Dis. 2002;22(2):137-44 [12016545.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):290-4 [12529648.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):281-304 [12871018.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Pharmacol Ther. 1989;43(1):139-54 [2675128.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1145-56 [2598264.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3400-7 [1692259.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1237-45 [7977654.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1316-25 [7557887.001]
  • [Cites] J Virol. 1996 Jul;70(7):4646-54 [8676491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15639-45 [9624157.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):41-9 [9934848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2934-41 [10378690.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Semin Liver Dis. 1999;19(3):243-52 [10518304.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] J Virol. 2005 Jan;79(1):214-24 [15596817.001]
  • [Cites] Methods Enzymol. 2005;392:381-405 [15644194.001]
  • [Cites] Toxicol Pathol. 2005;33(1):181-4 [15805070.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):942-4 [15611633.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):563-75 [16453009.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Methods. 2006 Sep;3(9):689-95 [16929313.001]
  • [Cites] Genome Biol. 2006;7(8):231 [16942630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14917-22 [17848523.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] J Virol. 2008 Jun;82(12):5887-911 [18400866.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19184-91 [18456653.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22186-92 [18524776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1630-6 [18665161.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):810-5 [18698328.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:42-65 [10836127.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):168-73 [10942533.001]
  • [Cites] J Virol. 2001 Aug;75(15):6969-76 [11435577.001]
  • (PMID = 19844192.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA03423; United States / NCI NIH HHS / CA / R01-CA89305; United States / NIDDK NIH HHS / DK / DK078424; United States / NCI NIH HHS / CA / F32-CA132312; United States / NCI NIH HHS / CA / R01 CA089305; United States / NCI NIH HHS / CA / F32 CA132312; United States / NIDDK NIH HHS / DK / R01 DK078424; United States / NCI NIH HHS / CA / P50-CA114747; United States / NCI NIH HHS / CA / R01 CA105102; United States / NCI NIH HHS / CA / R01-CA105102; United States / NCI NIH HHS / CA / P50 CA114747
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2839214
  •  go-up   go-down


2. Moya Herráiz A, Torres-Quevedo R, Mir Pallardó J: [Liver transplant in patients with hepatocellular carcinoma]. Cir Esp; 2008 Sep;84(3):117-24
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplant in patients with hepatocellular carcinoma].
  • [Transliterated title] Trasplante hepático en pacientes con carcinoma hepatocelular.
  • Liver transplant in patients with cirrhosis and hepatocellular carcinoma is indicated in the early stages of the disease, which can be achieved with early detection programs using liver ultrasound.
  • Surgery is the treatment of choice in these patients, and liver transplant, from a theoretical point of view, is the best.
  • The best liver transplant results are obtained in these patients using the Milan criteria, with survivals that exceed 70% and recurrence indices of 15%, at 5 years.
  • Nowadays we have the possibility of using neo-adjuvant treatments to transplant, such as arterial chemoembolisation, percutaneous ablation techniques, and even liver resection as a bridging technique.
  • The survival of patients transplanted due to liver cancer is similar to that obtained for other non-tumour diseases.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adult. Humans. Middle Aged. Spain / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783669.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Andújar RL, Orón EM, Herraiz AM, Cano CR, Rodríguez FS, Ibars EP, Burgueño Mde J, Castellanos FO, Pallardó JM: [Reflections on 250 interventions for colorectal carcinoma metastases to the liver]. Cir Esp; 2007 May;81(5):269-75
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reflections on 250 interventions for colorectal carcinoma metastases to the liver].
  • [Transliterated title] Reflexiones sobre 250 intervenciones de metástasis hepáticas de carcinoma colorrectal.
  • INTRODUCTION: The best results in the treatment of colorectal cancer metastases to the liver are currently achieved with surgical resection performed under high quality standards.
  • OBJECTIVES. To analyze the results and quality standards of the surgical treatment of colorectal cancer liver metastases in a referral liver unit over an 11-year period.
  • PATIENTS AND METHOD: From January 1995 to December 2005, 250 surgical interventions were performed in 221 patients diagnosed with colorectal cancer liver metastases, resulting in 201 hepatic resections.
  • CONCLUSIONS: Resection of colorectal cancer liver metastases is an effective therapeutic alternative if high current quality standards are achieved.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498456.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Sadaba LM, Garcia-Layana A, Garcia-Gomez PJ, Salinas-Alaman A: Sarcomatoid carcinoma and orbital apex syndrome. Eur J Ophthalmol; 2006 Jul-Aug;16(4):608-610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma and orbital apex syndrome.
  • PURPOSE: To report a case of sarcomatoid carcinoma and orbital apex syndrome in a previously healthy adult.
  • Eight months later, the patient presented with bone and liver metastases, and he died 4 months later.
  • CONCLUSIONS: Sarcomatoid carcinoma is an aggressive tumor that can produce compressive symptoms with very poor visual and survival prognoses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221641.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP: Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One; 2010 Jun 29;5(6):e11367
eagle-i research resources. PMID 20614008 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma.
  • BACKGROUND: Hydrodynamic injection is an effective method for DNA delivery in mouse liver and is being translated to larger animals for possible clinical use.
  • METHODOLOGY/PRINCIPAL FINDINGS: To study whether hydrodynamic delivery alone, or in conjunction with delivery of phiC31 integrase for long-term transgene expression, could facilitate tumor formation, we used a transgenic mouse model in which sustained induction of the human C-MYC oncogene in the liver was followed by hydrodynamic injection.
  • In contrast, when active or inactive phiC31 integrase and donor plasmid were supplied to the mouse liver, the median tumor latency was 153 days, similar to mice receiving no injection.
  • However, in groups lacking phiC31 integrase, hydrodynamic injection appeared to contribute to C-MYC-induced hepatocellular carcinoma in adult mice.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2005 Oct;12(4):763-71 [16084128.001]
  • [Cites] Methods Mol Biol. 2005;308:99-106 [16082029.001]
  • [Cites] J Mol Biol. 2006 Mar 17;357(1):28-48 [16414067.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Gene Ther. 2006 Aug;13(15):1188-90 [16672982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11730-5 [16864781.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):871-6 [16942446.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6298-304 [17098929.001]
  • [Cites] Curr Gene Ther. 2006 Dec;6(6):633-45 [17168696.001]
  • [Cites] Hum Gene Ther. 2006 Nov;17(11):1077-94 [17069535.001]
  • [Cites] Science. 2007 Jul 27;317(5837):477 [17656716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1866-75 [17991809.001]
  • [Cites] Gene Ther. 2008 Mar;15(6):452-62 [18004400.001]
  • [Cites] Cancer Gene Ther. 2008 Apr;15(4):225-30 [18259214.001]
  • [Cites] Mol Ther. 2008 Jun;16(6):1098-104 [18398428.001]
  • [Cites] PLoS One. 2008;3(6):e2493 [18560566.001]
  • [Cites] Lymphat Res Biol. 2008;6(3-4):149-54 [19093787.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):112-20 [19002165.001]
  • [Cites] Mol Ther. 2009 Mar;17(3):491-9 [19156134.001]
  • [Cites] BMC Biotechnol. 2009;9:31 [19341467.001]
  • [Cites] Mol Ther. 2010 Jan;18(1):161-70 [19844192.001]
  • [Cites] Gene Ther. 2010 Feb;17(2):217-26 [19847205.001]
  • [Cites] Mol Ther. 2010 Jul;18(7):1346-56 [20424600.001]
  • [Cites] Mol Biol Rep. 2010 Jul;37(6):2809-16 [19757154.001]
  • [Cites] Hum Gene Ther. 2010 Oct;21(10):1287-97 [20497035.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3926-34 [11359900.001]
  • [Cites] Nat Biotechnol. 2002 Nov;20(11):1124-8 [12379870.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):R425-7 [15182690.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Mod Pathol. 1996 Feb;9(2):95-8 [8657726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1735-7 [10428218.001]
  • [Cites] Gene Ther. 1999 Jul;6(7):1258-66 [10455434.001]
  • [Cites] Oncology. 1999;57(2):157-63 [10461064.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):399-408 [15727936.001]
  • [Cites] Mol Ther. 2005 May;11(5):695-706 [15851008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):419-24 [16387861.001]
  • (PMID = 20614008.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009302; United States / NCI NIH HHS / CA / CA89305-01A1; United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA034233; United States / NHLBI NIH HHS / HL / R01 HL068112; United States / NCI NIH HHS / CA / R01 CA089305; United States / NHLBI NIH HHS / HL / HL068112; United States / NHLBI NIH HHS / HL / R56 HL068112; United States / NCI NIH HHS / CA / CA09302
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2894073
  •  go-up   go-down


6. Ausín P, Gómez-Caro A, Rojo RP, Moradiellos FJ, Díaz-Hellín V, de Nicolás JL: [Spontaneous hemothorax caused by lung cancer]. Arch Bronconeumol; 2005 Jul;41(7):400-1
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hemotórax espontáneo por carcinoma broncogénico.
  • We describe the case of a 26-year-old man with spontaneous hemothorax secondary to large-cell carcinoma of the lung, with liver and bone metastases.
  • [MeSH-major] Carcinoma, Bronchogenic / complications. Hemothorax / etiology. Lung Neoplasms / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Radiography, Thoracic. Suction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029735.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Butte JM, Waugh E, Meneses M, Pruzzo R, Carvallo C, Redondo F, Suárez C, Parada H, Amaral H, de La Fuente H: [Fibrolamellar liver carcinoma: report of two cases and review of the literature]. Rev Med Chil; 2009 Mar;137(3):394-400
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibrolamellar liver carcinoma: report of two cases and review of the literature].
  • [Transliterated title] Carcinoma hepatocelular variedad fibrolamelar metastásico en menores de 20 años: Reporte de 2 casos tratados con intención curativa y revisión de la literatura.
  • Fibrolamellar hepatocellular carcinoma (FLC) is a rare histologic variant of hepatocellular carcinoma that appears most commonly in teenagers and young adults.
  • Diagnostic workup consisted of abdominal PET/CT and MR1 Imaging studies and tissue diagnosis was confirmed with percutaneous liver biopsy.
  • Both patients were treated with radical liver resection/tumor excision.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Biopsy. Fatal Outcome. Female. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Humans. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621182.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Chile
  •  go-up   go-down


8. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM: Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig Dis Sci; 2010 Nov;55(11):3052-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.
  • BACKGROUND: Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma.
  • As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma.
  • CASE PRESENTATION: A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 × 8 cm hepatocellular carcinoma replacing her right liver.
  • Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis.
  • CT volumetrics demonstrated a future liver remnant of 40%.
  • [MeSH-major] Alagille Syndrome / epidemiology. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


9. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Wilson FD, Fitzgerald SD, Kiupel M, Walker RL, Williams CB, Todd DJ: Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros). J Zoo Wildl Med; 2007 Jun;38(2):329-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros).
  • The liver was grossly enlarged and contained a smooth-surfaced nodular mass that occupied the majority of the right lobe of the liver.
  • The mass had a liver-like appearance exhibiting a tan-red coloration but having a soft consistency.
  • To our knowledge, this is the first report in the scientific literature of a naturally occurring case of hepatocellular carcinoma in a Nile lechwe or in any antelope species.
  • [MeSH-major] Antelopes. Carcinoma, Hepatocellular / veterinary. Liver Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679519.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Pila Pérez R, Pila Peláez R, Rosales Torres P, Holguín Prieto VA, Alzate Giraldo LF: [Sarcoidosis and fibrolamellar carcinoma of the liver]. An Med Interna; 2007 Sep;24(9):431-4
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcoidosis and fibrolamellar carcinoma of the liver].
  • [Transliterated title] Sarcoidosis y carcinoma fibrolamelar del hígado.
  • The case of 20-years female patient with the diagnosis of sarcoidosis associated to fibrolamellar carcinoma of the liver is presented.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Diseases / complications. Liver Neoplasms / pathology. Sarcoidosis / complications
  • [MeSH-minor] Adult. Female. Humans


12. Arroyo C, Palacios P, Uribe N, Barrera M, Feria G: [Uncommon metastases in renal carcinoma]. Gac Med Mex; 2005 Nov-Dec;141(6):543-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncommon metastases in renal carcinoma].
  • [Transliterated title] Metástasis poco frecuentes del carcinoma renal.
  • INTRODUCTION: Renal clear cell carcinoma (RCCCa) represents 2-3% of the neoplasms in the adult population, and can be metastastatic in up to 30% at the time of diagnosis.
  • MATERIAL AND METHODS: We reviewed retrospectively 15 years of patient records diagnosed with metastasic CaRCC different from: local lymph nodes, lung, bone or liver.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381513.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 42
  •  go-up   go-down


13. Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Ootao R, Horlad H, Baba Y, Miyase S, Takamori H, Baba H: Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus. Hepatol Res; 2009 May;39(5):525-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus.
  • In patients with no indication for a hepatic resection, the prognosis of adult hepatoblastoma is quite poor.
  • A 54-year-old man with hepatitis C virus-associated liver cirrhosis was initially treated with a hepatic resection for a hepatic tumor, 3 cm in diameter.
  • The tumor consisted of osteoid-like and cartilaginous foci, myxomatous stroma, and poorly differentiated hepatocellular carcinomatous cells and was diagnosed as a mixed epithelial and mesenchymal hepatoblastoma.
  • Two years after the first operation, multicentric hepatocellular carcinomas developed in the remnant liver and were successfully treated with a secondary hepatic resection combined with radio-frequency ablation.
  • To the best of our knowledge, the primary hepatoblastoma was the smallest such tumor reported and this is the first report of a metachronous hepatoblastoma and hepatocellular carcinoma in an adult hepatitis patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207587.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. del Pozo AC, De Battista S, Velasco D, Pianzola H, Rodríguez J: [Epidermoid carcinoma of gallbladder: analysis of our casuistic]. Acta Gastroenterol Latinoam; 2005;35(3):162-4
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinoma of gallbladder: analysis of our casuistic].
  • [Transliterated title] Carcinoma epidermoide de vesícula: análisis de nuestra casuística.
  • The squamous cell carcinoma represents only a 0-12% of all gallbladder tumors.
  • From these cases, 5 were squamous cell carcinomas, representing 2.41% of our series.
  • Liver involvement was observed in 4 of 5 patients at the moment of diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell. Gallbladder Neoplasms
  • [MeSH-minor] Adult. Argentina. Female. Humans. Male. Middle Aged. Retrospective Studies. Sex Distribution

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333974.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


15. Pérez Fentes DA, Blanco Parra M, Toucedo Caamaño V, Lema Grille J, Cimadevila García A, Villar Núñez M: [Atypical sites of metastatic renal carcinoma. Literature review]. Actas Urol Esp; 2005 Jul-Aug;29(7):621-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypical sites of metastatic renal carcinoma. Literature review].
  • [Transliterated title] Carcinoma renal metastásico de localización atípica. Revisión de la literatura.
  • OBJECTIVE: To review in the literature atypical sites of metastatic renal cell carcinoma, its onset, clinical features, diagnosis, treatment and prognosis.
  • METHODS: To review, using Medline database, atypical sites of metastatic renal cell carcinoma in the last five years Spanish literature.
  • RESULTS: There have been published 15 spanish articles about atypical metastatic renal cell carcinoma in the last five years.
  • CONCLUSIONS: Renal cell carcinoma represents about 3% of all adult malignancy neoplasms.
  • Its metastatic sites, in order of frequency, are lung, bone and liver, whether synchronic or methacronic.
  • The knowledge of this atypical sites in patients with renal cell carcinoma in the past can lead us to an earlier diagnosis and treatment which could change the evolution of the illness.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180312.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 19
  •  go-up   go-down


16. Cosme A, Montalvo I, Sánchez J, Ojeda E, Torrado J, Zapata E, Bujanda L, Gutiérrez A, Arenas I: [Type III glycogen storage disease associated with hepatocellular carcinoma]. Gastroenterol Hepatol; 2005 Dec;28(10):622-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type III glycogen storage disease associated with hepatocellular carcinoma].
  • [Transliterated title] Glucogenosis tipo III asociada a carcinoma hepatocelular.
  • It is characterized by accumulation of abnormal glycogen in the liver and, in 80% of patients, in muscle.
  • The liver can also show fibrosis and sometimes cirrhosis.
  • We present the case of a 31-year-old woman, diagnosed in childhood with type III glycogen storage disease, who 30 years after onset developed a hepatocellular carcinoma with portal thrombosis in the context of advanced cirrhosis.
  • This is the first case to be reported in the Spanish literature of type III glycogen storage disease associated with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Ascites / etiology. Biomarkers, Tumor / blood. Disease Progression. Fatal Outcome. Female. Glycogen Storage Disease Type III / complications. Humans. Liver Cirrhosis / etiology. Neoplasm Proteins / blood. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Glycogen Storage Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373012.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


17. Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, Turnes J, Aracil C, Del Val A, Pascasio JM, Rodríguez M, Bruix J: [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc); 2010 May 8;134(13):569-76
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
  • [Transliterated title] Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros.
  • BACKGROUND AND OBJECTIVE: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis and its current situation in Spain is not well known.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic / statistics & numerical data. Hepatectomy / statistics & numerical data. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Comorbidity. Early Diagnosis. Female. Hemochromatosis / epidemiology. Hepatitis, Viral, Human / epidemiology. Humans. Liver Cirrhosis / epidemiology. Male. Mass Screening. Niacinamide / analogs & derivatives. Obesity / epidemiology. Phenylurea Compounds. Prospective Studies. Pyridines / therapeutic use. Registries. Retrospective Studies. Spain / epidemiology. Treatment Outcome. Young Adult. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20036398.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Yttrium Radioisotopes; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


18. Sviteková M, Minár L, Pacovský Z: [Breast cancer in puerperium]. Klin Onkol; 2008;21(2):71-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma mammae v puerperiu.
  • AIM: This case study reports an occurence of a mammary gland carcinoma in woman during her pregnancy and puerperium.
  • The core cut biopsy revealed invasive ductal carcinoma grade 3 and the staging was determinated as T4b N2 M1 (liver).
  • Because of the high clinical stage of the disease, primary sugical therapy (modified radical mastectomy) was not indicated and the patient underwent neoadjuvant chemotherapy followed byradiotherapy.
  • There was a control PET scan after the chemotherapy which confirmed only residual tumor in the area of affected breast and no viable tumor cells in the area of the liver.
  • Additional reduction of the primary tumor lesion occured after the radiotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Puerperal Disorders / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102215.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


19. Freitas AC, Parolin MB, Stadnik L, Coelho JC: [Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil]. Arq Gastroenterol; 2007 Jul-Sep;44(3):189-94
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil].
  • [Transliterated title] Carcinoma hepatocelular: impacto do tempo em lista e das formas de tratamento pré-operatório na sobrevida do transplante de fígado cadavérico na era pré-MELD em um centro no Brasil.
  • BACKGROUND: Liver transplantation is the main treatment option for hepatocellular carcinoma in patients with cirrhosis.
  • AIM: Three months and 3 years survival were analysed in patients with cirrhosis and hepatocellular carcinoma and in patients with only cirrhosis.
  • METHODS: Charts of patients subjected to cadaveric liver transplantation at the Clinical Hospital of the Federal University of Paraná, Curitiba, PR, Brazil, between January 5th of 2001 and February 17th of 2006 were reviewed.
  • Patients were divided into two groups for 3 months and 1 year survival analysis: cirrhosis and hepatocellular carcinoma and cirrhosis only.
  • RESULTS: One hundred and forty six liver transplantation patients were analysed: 75 were excluded because of incomplete data and 71 were included.
  • Patients with hepatocellular carcinoma (n = 12) presented 3 months and 1 year survivals of 100%.
  • These rates were significantly higher than those of patients without hepatocellular carcinoma (n = 59; 72,8% and 69,4%).
  • Mean MELD score, mean Child-Pugh score and mean number of red blood cells transfused were significantly higher in patients without hepatocellular carcinoma.
  • The rate of Child-Pugh A and hepatitis C was higher in patients with hepatocellular carcinoma.
  • CONCLUSION: Patients with cirrhosis and hepatocellular carcinoma presented better 3 months and 1 year survival rates than patients with only cirrhosis.
  • This is possibly due to an early stage of cirrhosis at transplantation of patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data. Waiting Lists
  • [MeSH-minor] Adult. Brazil. Female. Humans. Male. Middle Aged. Patient Selection. Preoperative Care / methods. Retrospective Studies. Severity of Illness Index. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arq Gastroenterol. 2007 Jul-Sep;44(3):187-8 [18060268.001]
  • (PMID = 18060269.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


20. Ikeda S: [Adult-onset citrullinemia]. Brain Nerve; 2007 Jan;59(1):59-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset citrullinemia].
  • Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.
  • However, in 1995 the first CTLN2 patient who was successfully treated by living-related liver transplantation was reported and since then more than 30 patients had underwent this operation in our country, showing good outcomes.
  • No primary defect had not been found within ASS gene locus, but the causative gene of this disorder is now identified as the "citrin gene", which might act as a aspartate/glutamate transporter in mitochondria.
  • Different phenotypes are seen in the individuals with a citrin deficiency: neonatal intrahepatic cholestasis, juvenile-onset chronic pancreatitis and hepatocellular carcinoma without cirrhosis can precede the appearance of CTLN2.
  • [MeSH-minor] Administration, Oral. Adult. Age of Onset. Arginine / administration & dosage. Argininosuccinate Synthase. Calcium-Binding Proteins / genetics. Cholestasis, Intrahepatic / etiology. Chronic Disease. Glycerol / contraindications. Humans. Liver Neoplasms / etiology. Liver Transplantation. Mutation. Organic Anion Transporters / genetics. Pancreatitis / etiology. Phenotype

  • Genetic Alliance. consumer health - Citrullinemia.
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354380.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Organic Anion Transporters; 1340-08-5 / citrin; 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase; PDC6A3C0OX / Glycerol
  • [Number-of-references] 34
  •  go-up   go-down


21. Ikeda S: [Adult-onset citrullinemia]. No To Shinkei; 2007 Jan;59(1):59-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset citrullinemia].
  • Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.
  • However, in 1995 the first CTLN2 patient who was successfully treated by living-related liver transplantation was reported and since then more than 30 patients had underwent this operation in our country, showing good outcomes.
  • No primary defect had not been found within ASS gene locus, but the causative gene of this disorder is now identified as the "citrin gene", which might act as a aspartate/glutamate transporter in mitochondria.
  • Different phenotypes are seen in the individuals with a citrin deficiency: neonatal intrahepatic cholestasis, juvenile-onset chronic pancreatitis and hepatocellular carcinoma without cirrhosis can precede the appearance of CTLN2.
  • [MeSH-minor] Administration, Oral. Age of Onset. Arginine / administration & dosage. Argininosuccinate Synthase. Calcium-Binding Proteins / genetics. Cholestasis, Intrahepatic / etiology. Chronic Disease. Glycerol / contraindications. Liver Neoplasms / etiology. Liver Transplantation. Mutation. Organic Anion Transporters / genetics. Pancreatitis / etiology. Phenotype

  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228780.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Organic Anion Transporters; 1340-08-5 / citrin; 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase; PDC6A3C0OX / Glycerol
  • [Number-of-references] 34
  •  go-up   go-down


22. Liu J, Xie Y, Merrick BA, Shen J, Ducharme DM, Collins J, Diwan BA, Logsdon D, Waalkes MP: Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver. Toxicol Appl Pharmacol; 2006 Jun 15;213(3):216-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver.
  • Our prior work shows that in utero arsenic exposure alone is a complete transplacental carcinogen, producing hepatocellular carcinoma in adult male offspring but not in females.
  • The dermal application of TPA (2 mug/0.1 ml acetone, twice/week for 21 weeks) after transplacental arsenic did not further increase arsenic-induced liver tumor formation in adult males but significantly increased liver tumor formation in adult females.
  • Thus, for comparison, liver tumors and normal liver samples taken from adult male and female mice at necropsy were analyzed for aberrant gene/protein expression by microarray, real-time RT-PCR and Western blot analysis.
  • Arsenic/TPA treatment resulted in increased expression of alpha-fetoprotein, k-ras, c-myc, estrogen receptor-alpha, cyclin D1, cdk2na, plasminogen activator inhibitor-1, cytokeratin-8, cytokeratin-18, glutathione S-transferases and insulin-like growth factor binding proteins in liver and liver tumors from both male and female mice.
  • Alterations in these gene products were associated with arsenic/TPA-induced liver tumors, regardless of sex.
  • Thus, transplacental arsenic plus postnatal TPA exposure induced similar aberrant gene expression patterns in male and female mouse liver, which are persistent and potentially important to the mechanism of arsenic initiation of hepatocarcinogenesis.
  • [MeSH-major] Arsenic / toxicity. Gene Expression Regulation / drug effects. Liver / drug effects. Liver Neoplasms / metabolism. Prenatal Exposure Delayed Effects. Tetradecanoylphorbol Acetate / toxicity


23. Fernández-Ruiz M, Guerra-Vales JM, Llenas-García J, Colina-Ruizdelgado F: [Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years]. Rev Esp Enferm Dig; 2008 Oct;100(10):625-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years].
  • [Transliterated title] Carcinoma hepatocelular en el anciano: características clínicas, análisis de supervivencia y factores pronósticos en una cohorte de pacientes españoles mayores de 75 años.
  • AIMS: Hepatocellular carcinoma (HCC) remains poorly characterized in elderly patients with comorbid conditions, a fact that limits the clinical management of the disease.
  • CONCLUSIONS: The lower survival seen in elderly patients with HCC, beyond differences in tumor extension or liver failure, seems conditioned by the use of suboptimal treatment in this population.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Survival Analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119788.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Bustíos Sánchez C, Díaz Ferrer J, Román Vargas R, Dávalos Moscol M, Zumaeta Villena E: [Clinical - Epidemiological characteristics of the Hepatocellular Carcinoma and treatment in the departament of digestive system diseases of the National Hospital "Eduardo Rebagliatti Martins" (HNERM) - ESSALUD]. Rev Gastroenterol Peru; 2009 Jan-Mar;29(1):17-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical - Epidemiological characteristics of the Hepatocellular Carcinoma and treatment in the departament of digestive system diseases of the National Hospital "Eduardo Rebagliatti Martins" (HNERM) - ESSALUD].
  • [Transliterated title] Características clínico - epidemiológicas del Carcinoma Hepatocelular y su tratamiento en el departamento del aparato digestivo del HNERM ES-SALUD.
  • Hepatocellular carcinoma (CHC) is one of the leading causes of worldwide cancer mortality.
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hospital Departments. Hospitals. Humans. Male. Middle Aged. Peru. Prospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424404.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


25. Zuckermann M, Batignani G, Leo F, Tonelli F: [Surgical treatment of hepatocellular carcinoma: prognostic factors for long-term disease-free survival and tumor recurrence]. Suppl Tumori; 2005 May-Jun;4(3):S51-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hepatocellular carcinoma: prognostic factors for long-term disease-free survival and tumor recurrence].
  • [Transliterated title] La terapia chirurgica del carcinoma epatocellulare: fattori prognostici per la sopravvivenza a lungo termine libera da malattia e la recidiva tumorale.
  • Hepatocellular carcinoma mainly develops in a cirrhotic liver; in the majority of the patients chronic hepatitis or cirrhosis are virus-related and/or postalcoholic.
  • Liver resection is the gold standard treatment when there is no multifocality of the tumor and liver disease is not advanced (patients with Child-Pugh A score, or B in selected cases).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437898.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci; 2009 Dec;100(12):2249-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many studies on the risk factors and their carcinogenesis in adult hepatocellular carcinoma (HCC) have been reported, they remain poorly understood in childhood HCC.
  • The HBV pre-S2 deletion mutant at nt 4-57 which has a CD8 T-cell epitope could be responsible for the emergence and aggressive outcome of childhood HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Gene Deletion. Hepatitis B Surface Antigens / genetics. Hepatitis B virus / genetics. Liver Neoplasms / etiology. Protein Precursors / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719772.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Protein Precursors; 0 / presurface protein 2, hepatitis B surface antigen
  •  go-up   go-down


27. Zhong XG, He S, Yin W, Deng JY, Chen B: [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro]. Zhonghua Gan Zang Bing Za Zhi; 2005 Sep;13(9):644-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro].
  • OBJECTIVE: To explore the biological behavior of adult liver stem cells in a co-cultured system of them with hepatocellular carcinoma (HCC) cells without direct contact between the two kinds of cells.
  • METHODS: WB-F344, a kind of rat adult liver stem cell, and rat embryonic fibroblasts (REF) from a primary culture were engineered to express enhanced green fluorescent protein (EGFP) by recombinant adenoviral-mediated methods.
  • After the HCC cells grew to 40%-60% confluence in the culture dish with a 10-mm cell-free area, a similar number of WB-EGFP and REF-EGFP were placed in the blank areas respectively.
  • Their appearance was found not only when WB-EGFP cells were seeded into the cell-free area at the center of the dish, but also when seeded into the blank area at the extreme edge of the plate.
  • CONCLUSIONS: The results mean that adult liver stem cells have a biological behavior of selective tropism toward HCC cells in vitro, and suggest a possibility of using migratory liver stem cells as a delivery vehicle for gene therapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / cytology. Liver Neoplasms / pathology. Stem Cells / cytology

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174449.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Matsuno N, Iwamoto H, Nakamura Y, Hama K, Kihara Y, Konno O, Jojima Y, Akashi I, Mijiti A, Ashizawa T, Nagao T: ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma. Transplant Proc; 2008 Oct;40(8):2497-500
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma.
  • Living donor liver transplantation (LDLT) offers timely transplantation for patients with hepatocellular carcinoma (HCC).
  • In this article, we have described 8 adult HCC patients who successfully underwent LDLT from ABO-incompatible donors.
  • Our experience has shown that it is possible to control antibody-mediated humoral rejection and other complications in adult ABO-incompatible LDLT.
  • [MeSH-major] ABO Blood-Group System. Blood Group Incompatibility. Carcinoma, Hepatocellular / surgery. Immunosuppressive Agents / therapeutic use. Liver Neoplasms / surgery. Liver Transplantation / immunology. Living Donors
  • [MeSH-minor] Adult. Drug Therapy, Combination. Graft Rejection / prevention & control. Hepatitis B / surgery. Hepatitis C / surgery. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Middle Aged. Neoplasm Staging. Plasmapheresis. Splenectomy. Survival Analysis. Survivors. Treatment Outcome


29. Roman S: Adrenocortical carcinoma. Curr Opin Oncol; 2006 Jan;18(1):36-42
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma.
  • PURPOSE OF REVIEW: Adrenocortical carcinoma is a rare malignancy, accounting for 0.02% of all annual cancers reported.
  • While older studies purported an improved outcome for functional tumors in adult patients, this has not been borne out in more recent studies.
  • RECENT FINDINGS: Recent studies focusing on the tumorigenesis of adrenocortical carcinoma have focused on onco-developmental genes present in the fetal adrenal cortex, as well as local adrenal paracrine and autocrine effects of cellular peptides.
  • No significant advances in the treatment of adrenocortical carcinoma have been developed.
  • Surgery remains the mainstay for primary and recurrent disease, including select patients with isolated liver metastases.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357562.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Vascular Endothelial Growth Factor A; 104625-48-1 / Activins; 57285-09-3 / Inhibins; 78E4J5IB5J / Mitotane
  • [Number-of-references] 38
  •  go-up   go-down


30. Vilatobá M, Eckhoff DE, Contreras JL: [Liver transplantation of living donor adult-to-adult]. Rev Invest Clin; 2005 Mar-Apr;57(2):252-61
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation of living donor adult-to-adult].
  • End-stage liver disease is being treated by liver transplantation since more than 20 years.
  • Despite social and legislative efforts, the number of cadaveric organs suitable for liver transplantation has not grown to match the surplus of patients with end-stage liver disease.
  • With the growing discrepancy between donors and recipients, the median waiting time for liver transplantation has increased dramatically.
  • These include: split liver transplantation and transplantation of a part of the liver from living donors.
  • This review will focus on adult-to-adult transplantation of the right lobe from a living donor.
  • [MeSH-major] Liver Transplantation / methods. Living Donors
  • [MeSH-minor] Adult. Biopsy. Carcinoma, Hepatocellular / surgery. Fatty Liver / pathology. Health Services Needs and Demand / statistics & numerical data. Hepatectomy / adverse effects. Hepatectomy / methods. Hepatectomy / mortality. Hepatitis, Viral, Human. Humans. Liver / blood supply. Liver / cytology. Liver Neoplasms / surgery. Liver Regeneration. Organ Size. Postoperative Complications. Preoperative Care. Tissue and Organ Harvesting / ethics. Tissue and Organ Harvesting / methods. Tissue and Organ Procurement. Ultrasonography, Interventional. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524066.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 87
  •  go-up   go-down


31. Liu CL, Fan ST: Adult-to-adult live-donor liver transplantation: the current status. J Hepatobiliary Pancreat Surg; 2006;13(2):110-6
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-to-adult live-donor liver transplantation: the current status.
  • Adult-to-adult live-donor liver transplantation (ALDLT) has emerged successfully to partially relieve the refractory shortage of deceased donor grafts caused by the increasing demands of patients with endstage liver diseases.
  • Following the first successful live-donor liver transplantation (LDLT) for a child with biliary atresia in 1989, further extension of the technique, using left-lobe liver grafts for LDLT for large adolescents and adults, has resulted in satisfactory graft and patient survival outcomes.
  • However, small-for-size syndrome may occur in some patients with large body size, and in those with acute-on-chronic liver failure or severe portal hypertension.
  • To overcome the problem of graft-to-body-size mismatch, ALDLT, using a right-lobe liver graft was developed.
  • Although routine inclusion of the middle hepatic vein (MHV) in the right-lobe liver graft is still controversial, the importance of providing good venous drainage for the right anterior sector to ensure better early graft function has gained wide recognition.
  • However, there are scarce data supporting the contention that postoperative complication is related to the absence of the MHV in the left-liver remnant.
  • Dual-liver grafts and right-posterior sector grafts have been used in ALDLT, and are reported to result in satisfactory survival outcomes at selected transplant centers.
  • There is no strong evidence supporting the postulate that patients with hepatitis C infection have an inferior survival outcome after ALDLT when compared with recipients of a deceased-donor liver transplant.
  • ALDLT has contributed to satisfactory survival outcomes in patients with hepatocellular carcinoma (HCC).
  • It allows early surgery for the patients and eliminates the uncertainty of prolonged waiting for a deceased-donor liver graft, and the risks of dropout related to disease progression.
  • [MeSH-major] Liver Diseases / surgery. Liver Transplantation / methods. Living Donors
  • [MeSH-minor] Adult. Humans. Patient Selection

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16547671.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 55
  •  go-up   go-down


32. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


33. Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, Lee KU: Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl; 2010 May;16(5):678-84
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma.
  • Liver transplantation is regarded as an effective treatment for early hepatocellular carcinoma (HCC).
  • We investigated prognostic factors affecting survival after recurrence in patients who underwent adult living donor liver transplantation (LDLT) for HCC.
  • From October 1992 to December 2005, 138 adult patients underwent LDLT for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Liver Transplantation / mortality. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Living Donors. Male. Middle Aged. Multivariate Analysis. Patient Selection. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AASLD.
  • (PMID = 20440777.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Nojiri K, Omata M, Makuuchi M: Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease. Liver Transpl; 2006 Jul;12(7):1077-83
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease.
  • The selection of living donor liver transplantation (LDLT) recipients in regions where deceased donor liver transplantation (DDLT) is rarely performed might be different from that in other centers at which LDLT is an alternative option to DDLT.
  • Records of adult (age > or = 18 yr) patients referred to our center were reviewed to analyze the selection process of LDLT candidates.
  • Advanced hepatocellular carcinoma (HCC) was the most common reason for rejection (n = 55).
  • [MeSH-major] Donor Selection. Liver Failure / pathology. Liver Failure / surgery. Liver Transplantation. Living Donors
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Graft Rejection. Humans. Male. Middle Aged. Referral and Consultation. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 AASLD
  • (PMID = 16598784.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Ramírez Plaza CP, Santoyo Santoyo J, Domínguez López ME, Eloy-García Carrasco C, Cobo Dols M, Suárez Muñoz MA, Fernández Aguilar JL, de la Fuente Perucho A: [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy]. Arch Esp Urol; 2005 Mar;58(2):115-9
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy].
  • [Transliterated title] Carcinoma suprarrenal: supervivencia a 7 años libre de enfermedad tras resección completa del tumor primario y resecciones repetidas de recidivas locorregional y a distancia. Revisión a raiz de un caso con una pobre esperanza de vida inicial.
  • OBJECTIVES: We report the case of a female patient with adrenal carcinoma who had undergone surgery and presented with local-regional and distant recurrences, emphasizing the importance of the aggressive surgical treatment to achieve long-term survival which is unexpected sometimes.
  • METHODS/RESULTS: We report the case of a 29-year-old female patient who consulted for left flank pain, being diagnosed of an adrenal tumor by radiological tests; she underwent surgical excision of a left adrenal carcinoma (stage II).
  • Later on she presented with local-regional recurrences (2 times) and distant metastases (liver) undergoing excision in three procedures.
  • Nevertheless, an aggressive surgical approach of local recurrences and metastasic disease may significantly prolong patient's survival and, sometimes, leave the patient disease free several years after the diagnosis of the primary tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Carcinoma / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Reoperation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847268.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Lang H, Sotiropoulos GC, Dömland M, Frühauf NR, Paul A, Hüsing J, Malagó M, Broelsch CE: Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg; 2005 Feb;92(2):198-202
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis.
  • BACKGROUND: Hepatocellular carcinoma (HCC) arising in normal liver parenchyma is rare and the outcome after hepatectomy is not well documented.
  • METHODS: Between June 1998 and September 2003, 33 patients without viral hepatitis underwent resection for HCC in a non-cirrhotic, non-fibrotic liver.
  • CONCLUSION: These data justify hepatic resection for HCC arising in non-cirrhotic, non-fibrotic liver without underlying viral hepatitis.
  • Liver transplantation is rarely indicated because the outcome is good after resection of tumours without vascular infiltration, whereas vascular invasion is invariably associated with diffuse extrahepatic recurrence.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609381.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Vitale A, Boccagni P, Brolese A, Neri D, Srsen N, Zanus G, Pagano D, Pauletto A, Bonsignore P, Scopelliti M, D'Amico FE, Ometto G, Polacco M, Burra P, Gambato M, Feltracco P, Romano A, Cillo U: Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation? Transplant Proc; 2009 May;41(4):1264-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation?
  • BACKGROUND: Tumor progression before liver transplantation (OLT) is the main cause of dropout from the waiting list (WL) of patients with hepatocellular carcinoma (HCC).
  • Adult patients with benign chronic liver disease enlisted for primary OLT in the same period represented the control group.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Patient Dropouts
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Waiting Lists. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460534.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Gruttadauria S, Marsh JW, Cintorino D, Biondo D, Luca A, Arcadipane A, Vizzini G, Volpes R, Marcos A, Gridelli B: Adult to adult living-related liver transplant: report on an initial experience in Italy. Dig Liver Dis; 2007 Apr;39(4):342-50
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult to adult living-related liver transplant: report on an initial experience in Italy.
  • INTRODUCTION: Living-related liver transplantation has become the treatment of choice for many liver diseases.
  • We present our initial analysis of 53 cases of adult to adult living-related liver transplantation performed in a single institute in Italy.
  • MATERIALS AND METHODS: From January 2002 to September 2006, we performed 53 adult to adult living-related liver transplantations.
  • Recipients (ages 18-68) suffered from cirrhosis secondary to viral etiology (18), hepatocellular carcinoma with viral cirrhosis (24), cystic fibrosis (2), primary biliary cirrhosis (2), hepatocellular carcinoma with non-viral cirrhosis (2), alcoholic cirrhosis (1), ornithine transcarbamylase deficiency (OTC), (1) criptogenic cryptogenic cirrhosis, (1) primary sclerosing cholangitis, (1) biliary atresia and metastatic carcinoid (1).
  • Donor liver resection resulted in 51 right hepatectomies and two left hepatectomies.
  • CONCLUSION: Adult to adult living-related liver transplantation represents a resource to be used in confronting organ shortage, and is a valuable option for decreasing mortality and drop out from the waiting list.
  • [MeSH-major] Liver Transplantation / statistics & numerical data. Living Donors
  • [MeSH-minor] Adolescent. Adult. Donor Selection. Female. Graft Rejection / epidemiology. Graft Survival. Humans. Italy / epidemiology. Liver Diseases / mortality. Liver Diseases / surgery. Male. Middle Aged. Recurrence. Reoperation / statistics & numerical data. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337259.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


39. Yan LN, Li B, Zeng Y, Wen TF, Wang WT, Yang JY, Xu MQ, Chen ZY, Zhao JC, Ma YK, Wu H: [Analysis of fifty adult to adult living donor liver transplantation]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun;38(3):513-7
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of fifty adult to adult living donor liver transplantation].
  • OBJECTIVE: To investigate the safety of adult-to-adult living donor liver transplantation (AALDLT), which means how to make the life safeties of both adult donor and recipient who are transplanted with the right lobe of liver.
  • METHODS: From January 2002 to July 2006, 50 A-ALDLT were performed at West China Hospital, Sichuan University, which consisted of 47 cases with right lobe graft without middle hepatic vein (MHV) and 3 cases with the dual graft of liver lobes (one cases with two left lobes, 2 with one right and one left lobe).
  • The majority of adult liver recipients suffered originally from the hepatitis B with liver cirrhosis (60%), hepatocellular carcinoma (30%) as primary diseases, and 10 cases among them had the model of end-stage liver disease (MELD) score more than 25.
  • RESULTS: From 52 living donors, 49 right liver lobes and 3 left lobes were obtained.
  • All of the donor remnant liver volumes were larger 35% of the whole liver volume.
  • 69% of donors undergoing complications in 50 adult recipients.
  • CONCLUSION When preoperative CT volume showed the volume of remnant liver is greater than 35% of whole liver volume, and the ratio of right lobe graft volume to recipient's standard live volume is more than 40% , A-ALDLT using right lobe graft should be very safe procedure for both donors and recipients, otherwise the dual graft liver transplantation should be considered.
  • [MeSH-major] Liver Transplantation / methods. Living Donors
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Liver / pathology. Liver / radiography. Male. Middle Aged. Organ Size. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593845.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Abdullah K, Abdeldayem H, Hali WO, Sakran A, Yassen K, Abdulkareem A: Twenty cases of adult-to-adult living-related liver transplantation: single-center experience in Saudi Arabia. Transplant Proc; 2005 Sep;37(7):3144-6
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty cases of adult-to-adult living-related liver transplantation: single-center experience in Saudi Arabia.
  • BACKGROUND: The deceased donor organ shortage has forced surgeons to implement innovations, including living-related liver transplantation (LRLT).
  • OBJECTIVE: To present the first 20 cases of adult LRLT in a single center in Saudi Arabia.
  • One patient received combined liver and kidney grafts.
  • RESULTS: All cases had liver cirrhosis.
  • Three cases had associated hepatocellular carcinomas.
  • Recipients complications included biliary complications (35%), acute rejection (20%), hepatitis C reactivation (20%), hepatic vein stenosis (10%), hepatic artery stenosis (5%), and hepatocellular carcinoma recurrence (5%).
  • CONCLUSIONS: LRLT has become a standard option in adults with end-stage liver failure in our center.
  • [MeSH-major] Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy / methods. Hepatitis B / complications. Hepatitis C / complications. Humans. Kidney Transplantation / methods. Length of Stay. Liver Diseases / surgery. Liver Failure / surgery. Living Donors / statistics & numerical data. Male. Middle Aged. Nuclear Family. Postoperative Complications / classification. Retrospective Studies. Tissue and Organ Harvesting / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213331.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG: Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl; 2005 Oct;11(10):1265-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations.
  • Current selection criteria of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) were derived from the outcomes of cadaveric donor LT (CDLT).
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods. Liver Transplantation / statistics & numerical data. Living Donors. Tissue Donors
  • [MeSH-minor] Adult. Aged. Cadaver. Female. Humans. Korea. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome


42. Laurent A, Tayar C, Andréoletti M, Lauzet JY, Merle JC, Cherqui D: Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg; 2009;16(3):310-4
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma.
  • BACKGROUND/PURPOSE: In patients with hepatocellular carcinoma (HCC), a previous liver resection (LR) may compromise subsequent liver transplantation (LT) by creating adhesions and increasing surgical difficulty.
  • We report the operative results of LT after laparoscopic or open liver resection (OLR).
  • RESULTS: In the LLR group, absence of adhesions was associated with straightforward access to the liver in all cases.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Cohort Studies. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Laparotomy / adverse effects. Laparotomy / methods. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2009 Jul;15(7):813-4 [19582953.001]
  • (PMID = 19280110.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Schiel KA: An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis. Med Hypotheses; 2006;67(1):93-109
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis.
  • This model proposes that primary carcinomatous tumors and almost all metastases are extramedullary hematopoietic tissue formed to compensate for reduced hematopoietic activity in the bone marrow.
  • Specific carcinoma morphologies are equated to stages in endochondral bone and marrow formation and, as such, cancer cell identity varies with morphology.
  • Tubular breast carcinoma, with its single layer of osteoblast-like carcinoma cells encircling small lumens and long branching tubules, is equated to the trabecular stage of marrow formation during which osteoblasts surround small pieces of calcified cartilage and begin secreting osteoid that will form the trabeculae.
  • Lobular carcinoma in situ consists of cancer cell clusters separated by narrow clear spaces that, under high magnification, appear vascular.
  • If this model is correct it necessitates a change in the treatment of carcinoma.
  • [MeSH-major] Carcinoma / etiology. Hematopoiesis, Extramedullary. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Bone Marrow Cells. Granulocytes / metabolism. Hematopoietic Stem Cells / cytology. Humans. Leukemia / metabolism. Models, Biological. Neoplasm Metastasis. Primary Myelofibrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540257.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


44. Herr I, Groth A, Schemmer P, Büchler MW: Adult stem cells in progression and therapy of hepatocellular carcinoma. Int J Cancer; 2007 Nov 1;121(9):1875-82
Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult stem cells in progression and therapy of hepatocellular carcinoma.
  • Hepatocellular carcinoma is one of the most aggressive solid tumours associated with poor prognosis.
  • The medical community is currently experiencing a wave of enthusiasm for clinical trials, in which adult stem/progenitor cells are used for liver regeneration.
  • Stem cells may contribute to fibrosis or give rise to hepatic cancer stem cells as a source of hepatocellular carcinoma.
  • This review outlines the current state of knowledge in progression of liver disease and highlights the function of adult stem cells in disease and therapy.
  • [MeSH-major] Adult Stem Cells / transplantation. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / therapy
  • [MeSH-minor] Animals. Cell Differentiation. Disease Progression. Humans. Regeneration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17685426.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


45. Treska V, Skalický T, Sutnar A, Liska V: [Surgical management of the colorectal carcinoma liver metastases]. Rozhl Chir; 2009 Feb;88(2):69-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of the colorectal carcinoma liver metastases].
  • INTRODUCTION: Unfortunately, the Czech Republic rates of the colorectal carcinoma are the highest in the world.
  • Surgical procedures for colorectal carcinoma liver metastases (JMKRK) are well established and have good long-term outcomes.
  • AIM: The aim of the study was to assess own results with a reference on modern trends in liver surgery.
  • SUBJECTS AND METHODOLOGY: From 01- 01- 2000 to 01-12- 2008, a total of 442 liver procedures in 346 patients with colorectal carcinoma liver metastases were performed in the Faculty Hospital and the Charles University Medical Faculty Surgical Clinic in Plzen.
  • Five years following the liver procedure for the colorectal carcinoma liver metastases, 34.0% of the subjects are surviving.
  • 3 years following radiofrequency ablation (RFA) of the colorectal carcinoma liver metastases, 35.5% of the patients are surviving.
  • CONCLUSION: Nowadays, surgical management of the colorectal carcinoma liver metastases is the method of choice.
  • The other alternative is radiofrequency ablation (RFA) in non-resectable colorectal carcinoma liver metastases.
  • Therefore, the new trends in liver surgery include several-stage/phase, combined procedures and re-resections, aimed to improve resecability of the colorectal carcinoma liver metastases with low patient postoperative mortality and morbility rates.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19413263.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


46. Lu XY, Xu JM, Zhong YS, Ren L, Lai YH, Qin XY: [Evaluation of cyclooxygenase-2 in the prediction of liver metastasis of colorectal carcinoma]. Zhonghua Wai Ke Za Zhi; 2007 Jan 1;45(1):54-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of cyclooxygenase-2 in the prediction of liver metastasis of colorectal carcinoma].
  • OBJECTIVE: To investigate the expression of cyclooxygenase-2 (COX-2) in colorectal carcinoma and its correlation with liver metastasis of colorectal carcinoma.
  • METHODS: The expression of COX-2 was detected using immunohistochemical methods in 30 colorectal carcinoma tissues without liver metastasis, 30 with preoperative liver metastasis, 30 with postoperative liver metastasis and 30 surrounding normal colorectal tissues.
  • RESULTS: The expression of COX-2 in colorectal carcinoma was significantly higher than that in surrounding normal colorectal tissue (P < 0.05), and meanwhile, its level in colorectal carcinoma without liver metastasis was significantly lower than those in tissues with preoperative or postoperative liver metastasis (P < 0.05).
  • The COX-2 level had no correlation with gender, age, histological type, histological grade or the preoperative serum CEA and CA 19-9 levels in colorectal carcinoma (P > 0.05), but it was related to Dukes stages and lymph node metastasis.
  • CONCLUSIONS: COX-2 plays a role in the course of generation, development and metastasis of colorectal carcinoma.
  • The high expression of COX-2 in colorectal carcinoma tissues may be considered as an indicator for liver metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Cyclooxygenase 2 / biosynthesis. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403293.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


47. Beer S, Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, Felsher DW: Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS One; 2008 Jun 18;3(6):e2493
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis.
  • BACKGROUND: Overexpression of the human c-MYC (MYC) oncogene is one of the most frequently implicated events in the pathogenesis of hepatocellular carcinoma (HCC).
  • Previously, we have shown in a conditional transgenic mouse model that MYC overexpression is restrained from inducing mitotic cellular division and tumorigenesis in the adult liver; whereas, in marked contrast, MYC induces robust proliferation associated with the very rapid onset of tumorigenesis in embryonic and neonatal mice.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here, we show that non-genotoxic hepatotoxins induce changes in the liver cellular context associated with increased cellular proliferation and enhanced tumorigenesis.
  • Both 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) and carbon tetrachloride (CCl(4)) cooperate with MYC to greatly accelerate the onset of liver cancer in an adult host to less than 7 days versus a mean latency of onset of over 35 weeks for MYC alone.
  • These hepatotoxin-enhanced liver tumors grossly and histologically resemble embryonic and neonatal liver tumors.
  • Importantly, we found that MYC overexpression is only capable of inducing expression of the mitotic Cyclin B1 in embryonic/neonatal hosts or adult hosts that were treated with either carcinogen.
  • CONCLUSION/SIGNIFICANCE: Our results suggest a model whereby oncogenes can remain latently activated, but exposure of the adult liver to hepatotoxins that promote hepatocyte proliferation can rapidly uncover their malignant potential.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Hepatology. 1997 Jan;25(1):133-41 [8985279.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6487-93 [11522645.001]
  • [Cites] Adv Cancer Res. 2002;84:81-154 [11885563.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):123-34 [9426068.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1577-89 [9626061.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):103-9 [10068199.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2934-41 [10378690.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Semin Liver Dis. 1999;19(3):243-52 [10518304.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Hepatology. 2002 Sep;36(3):623-30 [12198654.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2019-26 [12466118.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11881-8 [12902545.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Arch Pathol. 1968 Mar;85(3):275-9 [5640336.001]
  • [Cites] CRC Crit Rev Toxicol. 1973 Nov;2(3):263-97 [4357489.001]
  • [Cites] J Clin Pathol. 1973 Dec;26(12):936-42 [4784502.001]
  • [Cites] Am J Pathol. 1975 Oct;81(1):237-50 [1180333.001]
  • [Cites] Am J Pathol. 1977 Nov;89(2):477-82 [920780.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):780-6 [2581126.001]
  • [Cites] Carcinogenesis. 1987 Nov;8(11):1737-40 [3664968.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5522-7 [3416306.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2703-7 [2649891.001]
  • [Cites] Oncogene. 1989 Jun;4(6):715-24 [2543942.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1347-63 [2474256.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4894-900 [2474377.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1278-85 [1847661.001]
  • [Cites] Differentiation. 1990 Oct;45(1):29-37 [2292360.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2611-20 [1708696.001]
  • [Cites] Exp Cell Res. 1991 Jul;195(1):59-65 [1711473.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1991;31:253-87 [2064376.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1719-23 [8467484.001]
  • [Cites] Toxicol Appl Pharmacol. 1993 Apr;119(2):275-9 [8480336.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4329-36 [8364928.001]
  • [Cites] Arch Environ Contam Toxicol. 1993 Aug;25(2):260-6 [8368868.001]
  • [Cites] J Cell Biol. 1994 Jul;126(1):223-33 [8027180.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):7-11 [7805043.001]
  • [Cites] Mol Carcinog. 1996 Apr;15(4):261-9 [8634084.001]
  • [Cites] J Cell Biochem. 1996 Feb;60(2):161-72 [8655627.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):407-28 [8701981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):168-73 [10942533.001]
  • (PMID = 18560566.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U56 CA112973; United States / NIDDK NIH HHS / DK / DK56399; United States / NCI NIH HHS / CA / 1P20 CA112973; United States / NCI NIH HHS / CA / R01 CA089305; United States / NCI NIH HHS / CA / R01 CA105102; United States / NCI NIH HHS / CA / 3R01CA089305-03S1; United States / NCI NIH HHS / CA / R01 CA085610; United States / NCI NIH HHS / CA / R01-CA85610; United States / NCI NIH HHS / CA / R01-CA105102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3,5-diethoxycarbonyl-1,4-dihydrocollidine; 0 / Carcinogens; 0 / DNA Primers; 0 / Pyridines; 632-93-9 / Dicarbethoxydihydrocollidine; CL2T97X0V0 / Carbon Tetrachloride
  • [Other-IDs] NLM/ PMC2423614
  •  go-up   go-down


48. Malik SM, Gupte PA, de Vera ME, Ahmad J: Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol; 2009 Jul;7(7):800-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
  • BACKGROUND & AIMS: The increasing incidence of hepatocellular carcinoma in the United States is only partially accounted for by hepatitis C virus (HCV) infections.
  • The prevalence of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (NASH) is not known; guidelines from the American Association for the Study of Liver Diseases do not recommend surveillance imaging.
  • We sought to determine the prevalence of hepatocellular carcinoma among patients undergoing liver transplantation for NASH-related cirrhosis and their outcome after surgery, compared with controls.
  • METHODS: We reviewed the records of adult patients with NASH cirrhosis who underwent liver transplantation by using a prospectively collected database from a single center.
  • Data from patients with NASH cirrhosis were compared with matched controls who received transplantation for primary biliary cirrhosis/primary sclerosing cholangitis, alcoholic liver disease, or HCV.
  • RESULTS: Seventeen of 98 patients (17%) with NASH cirrhosis were diagnosed with hepatocellular carcinoma.
  • Six patients were diagnosed with hepatocellular carcinoma incidentally on explant.
  • Survival after liver transplantation was 88% after mean follow-up of 2.5 years.
  • The number of NASH patients known to have hepatocellular carcinoma before liver transplantation was greater than the number of patients with primary biliary cirrhosis/primary sclerosing cholangitis and comparable to the number of patients with alcoholic liver disease and HCV.
  • CONCLUSIONS: Patients with NASH cirrhosis are at risk for developing hepatocellular carcinoma; patients with NASH cirrhosis, especially men older than 50 years, should undergo surveillance imaging.
  • Patients with NASH and hepatocellular carcinoma have good outcomes after liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / surgery. Fatty Liver / complications. Fatty Liver / epidemiology. Liver Transplantation
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Risk Factors. Sex Factors. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2009 Oct;15(10):1367-8 [19806686.001]
  • (PMID = 19281869.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Burri E, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R: Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol; 2006 Apr;18(4):437-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver.
  • Liver-cell adenomas are benign lesions of the liver occurring predominantly in young women.
  • Hepatocellular carcinomas in most of the cases arise in a cirrhotic liver during the fifth or sixth decade.
  • Tests for chronic liver diseases were negative.
  • The tumour was surgically removed and a hepatocellular carcinoma arising within a liver-cell adenoma in a non-cirrhotic liver was found.
  • Malignant transformation of liver-cell adenoma has only been reported in a few case reports.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538118.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


50. Castaing D, Salloum C, Azoulay D, Adam R, Vibert E, Veilhan LA, Karam V, Saliba F, Ichaï P, Samuel D: Adult liver transplantation: the Paul Brousse experience. Clin Transpl; 2007;:145-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult liver transplantation: the Paul Brousse experience.
  • During the past 3 decades, more than 2,250 liver transplants were performed at Paul Brousse Hospital.
  • Our group has developed a variety of approaches to liver transplantation, including: 1.
  • 3. Transplantation for hepatocellular carcinoma on a cirrhotic liver with a single tumor <5 cm or <3 tumors <3 cm.
  • More than 100 livers obtained after hepatectomy from FAP patients were transplanted as "domino" living donor livers to patients with unresectable liver cancers with a 5-year survival rate of 64%.
  • In some domino recipients, symptoms of FAP disease occurred more rapidly than expected and this could be an indication for a second transplantation of a non FAP-liver.
  • 5. Split-liver transplantation for pediatric patients.
  • 6. Split-liver transplantation for 2 adults.
  • 7. Adult -to-adult living-related liver transplantation.
  • 8. Liver retransplantation with good results in the elective situation.
  • [MeSH-major] Graft Survival. Liver Failure / mortality. Liver Failure / surgery. Liver Transplantation / mortality
  • [MeSH-minor] Adult. Humans. Tissue Donors / statistics & numerical data. Tissue Donors / supply & distribution

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637466.001).
  • [ISSN] 0890-9016
  • [Journal-full-title] Clinical transplants
  • [ISO-abbreviation] Clin Transpl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


51. Guettier C: [Which stem cells for adult liver?]. Ann Pathol; 2005 Feb;25(1):33-44
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Which stem cells for adult liver?].
  • While hepatocytes can be considered conceptually as unipotent stem cells, the presence of true stem or progenitor cells within adult livers has been largely debated.
  • In the normal liver, the identification of progenitor cells with a panel of markers including c-kit, CD34, Ov6, CK7, CK19, chromogranine A, CD56 remains difficult because these cells are very few and most of the markers are not specific.
  • Mechanisms leading to the activation and the proliferation of hepatic progenitor cells are still largely unknown: they involve growth factors as the stem cell factor, ligand of c-kit, cytokines, chemokines as SDF1 a and vagal or sympathetic innervatioñ.
  • Other potential stem cells for liver could be hematopoietic stem cells from bone marrow.
  • It does occur in extreme experimental conditions either by true transdifferentiation or cell fusion.
  • The shared property of stem cells and tumor cells to proliferate endlessly, rises the question of the potential role of progenitor cells in liver carcinogenesis.
  • The identification of progenitor cells close to murine oval cells in the human liver raises the hypothesis of a potential role of these cells in the development of human liver tumors.
  • Liver progenitor cells have been identified morphologically and phenotypically in dysplastic foci of cirrhotic livers and hepatocellular adenomas.
  • More generally speaking, typical hepatocellular carcinomas and cholangiocarcinomas are at the two ends of a spectrum which includes transitional-type tumors intermediate between hepatocellular carcinoma and cholangiocarcinoma and combined hepato-cellular cholangiocarcinoma; these intermediate and combined types can be more easily explained as deriving from progenitor cells.
  • Despite the difficulties, the doubts and the potential dangers, new experimental modalities to obtain efficient repopulation of the liver from bone marrow stem cells are currently under study: exogenous administration of cytokines and chemokines involved in cell homing and differentiation or development of selective pressure strategies.
  • Other cell types as intra-hepatic progenitor cells, bone marrow multipotent adult progenitor cells (MAPCs) or fetal hepatocytes could be alternative sources for liver cell therapy.
  • Thus, progressing knowledge about stem cells in adult liver would allow to better understand mechanisms of hepatic homeostasia and regeneration and would open the way to cell-based therapy for liver diseases.
  • [MeSH-major] Hepatocytes. Liver / cytology. Stem Cells
  • [MeSH-minor] Adult. Animals. Bone Marrow Cells / cytology. Cell Differentiation. Cell Division. Hematopoietic Stem Cells / cytology. Humans. Immunophenotyping. Liver Diseases / surgery. Liver Neoplasms / pathology. Sensitivity and Specificity. Stem Cell Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981930.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 59
  •  go-up   go-down


52. Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, Nakamura T, Fukui I: Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res; 2009 Feb 15;15(4):1170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.
  • PURPOSE: To determine the incidence of Xp11 translocation renal cell carcinoma (RCC) in adult patients using cytogenetics and immunohistochemstry.
  • EXPERIMENTAL DESIGN: Cytogenetic studies were prospectively done using tumor samples from 443 consecutive adult Japanese patients (ages 15-89 years) who underwent nephrectomy for RCC.
  • Of these 2, 1 had pulmonary metastasis at presentation, and the other developed liver metastasis 12 months after nephrectomy and died of the disease.
  • CONCLUSIONS: This is the first report to determine the incidence of Xp11 translocation RCC in adult patients.
  • [MeSH-major] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / analysis. Carcinoma, Renal Cell / genetics. Chromosomes, Human, X. Kidney Neoplasms / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-met. Receptors, Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228722.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / TFE3 protein, human; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


53. Nara M, Toyoki Y, Hakamada K, Narumi S, Ishido K, Sugai M, Munakata H, Ito E, Sasaki M: Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma. Transplant Proc; 2008 Oct;40(8):2828-9
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma.
  • INTRODUCTION: Pediatric hepatocellular carcinoma (HCC) is an uncommon disease with a poor prognosis.
  • There are few reports about liver transplantation for pediatric adult-type HCC.
  • We experienced a case of living donor liver transplantation (LDLT) for a child with recurrent pediatric adult-type HCC.
  • However, his alpha-fetoprotein level increased and a computed tomography (CT) scan showed recurrent tumor in his remnant liver in October 2006.
  • However, CT revealed multiple liver tumors after chemotherapy in December 2006.
  • CONCLUSION: Liver transplantation in conjunction with chemotherapy may have an increasing role in the management of pediatric HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Living Donors
  • [MeSH-minor] Adult. Child. Female. Hepatectomy. Humans. Male. Neoplasm Recurrence, Local. Treatment Outcome. alpha-Fetoproteins / metabolism


54. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One; 2007 Aug 15;2(8):e753
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in adult life.
  • Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 12;355(9203):561-5 [10683019.001]
  • [Cites] J Infect Dis. 2006 Jun 1;193(11):1528-35 [16652281.001]
  • [Cites] Pediatrics. 2001 Apr;107(4):626-31 [11335734.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):569 [12228132.001]
  • [Cites] Scand J Infect Dis. 2002;34(8):610-4 [12238579.001]
  • [Cites] Vaccine. 2002 Oct 4;20(29-30):3472-6 [12297392.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):157-63 [12586980.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5782-7 [2822233.001]
  • [Cites] J Med Virol. 1988 Apr;24(4):377-84 [3367136.001]
  • [Cites] Lancet. 1991 Mar 30;337(8744):747-50 [1672389.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):250-4 [7989718.001]
  • [Cites] J Infect Dis. 1997 Jun;175(6):1494-7 [9180192.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):933-7 [9564478.001]
  • [Cites] Vaccine. 1998 Apr;16(6):624-9 [9569474.001]
  • [Cites] J Infect Dis. 1999 Feb;179(2):489-92 [9878036.001]
  • [Cites] Vaccine. 1999 Apr 23;17(17):2162-5 [10367949.001]
  • [Cites] Vaccine. 1999 Jun 4;17(20-21):2661-6 [10418916.001]
  • [Cites] Vaccine. 1999 Aug 6;17(23-24):2946-50 [10462228.001]
  • [Cites] Vaccine. 2005 Dec 30;23(50):5792-7 [16303217.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S1-3 [16461208.001]
  • [Cites] Vaccine. 2000 Nov 22;19(7-8):877-85 [11115711.001]
  • (PMID = 17710152.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071425; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ PMC1940311
  • [General-notes] NLM/ Original DateCompleted: 20070822
  •  go-up   go-down


55. Fujimoto Y, Nakanishi Y, Sekine S, Yoshimura K, Akasu T, Moriya Y, Shimoda T: CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis Colon Rectum; 2005 Oct;48(10):1883-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in colorectal carcinoma correlates with liver metastasis.
  • PURPOSE: If it were possible to identify the features of primary colorectal carcinoma that were associated with liver metastasis, these features could be used as predictors of liver metastasis.
  • METHODS: From January 1995 to December 1997, 648 consecutive cases of colorectal carcinoma were recorded at the Department of Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • We evaluated clinicopathologic and immunohistochemical factors (age, gender, tumor location, gross type, size, histologic type, dedifferentiation of invasive front, depth of invasion, lymphatic invasion, venous invasion, lymph-node metastasis, and expression of CD10, MUC2, and human gastric mucin) in 505 of these patients who had undergone resection of T2/T3/T4 colorectal carcinomas to clarify the correlation between these factors and liver metastasis.
  • RESULTS: Liver metastases, including unresectable, were detected in 122 patients (24 percent), all of whom had been followed for at least five years.
  • Univariate analysis revealed that liver metastasis was significantly associated with tumor size, histologic type, dedifferentiation of invasive front, depth of invasion, lymphatic invasion, venous invasion, lymph-node metastasis, and CD10 expression.
  • Multivariate analysis revealed that invasion deeper than the subserosa, venous invasion, lymph-node metastasis, and CD10 expression were significantly associated with liver metastases.
  • CONCLUSIONS: CD10 expression in colorectal carcinoma is a good predictor of liver metastasis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Colorectal Neoplasms / chemistry. Liver Neoplasms / chemistry. Neprilysin / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastric Mucins / analysis. Humans. Male. Middle Aged. Mucin-2. Mucins / analysis. Neoplasm Metastasis. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175325.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gastric Mucins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


56. Lee KK, Kim DG, Moon IS, Lee MD, Park JH: Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol; 2010 Jan 1;101(1):47-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.
  • PURPOSE: Liver resection (LR) and liver transplantation (LT) are considered the only two potentially curative treatments for hepatocellular carcinoma (HCC).
  • HCC recurred more frequently after resection (51.5%) than it did after transplantation (29.5%) (P < 0.001), and HCC recurrence developed in the liver more frequently after LR than it did after LT (P = 0.002).
  • CONCLUSION: LT should be considered as the primary treatment in patients with HCC within the Milan criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


57. Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, Ha TY, Song GW: Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl; 2007 May;13(5):741-6
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma.
  • Salvage liver transplantation has been performed for recurrent hepatocellular carcinoma (HCC) or deterioration of liver function after primary liver resection.
  • Because prior liver resection per se is an unfavorable condition for living donor liver transplantation (LDLT), we assessed the technical feasibility of LDLT after prior hepatectomy, and we compared the outcome of salvage LDLT with that of primary LDLT in HCC patients.
  • Of 342 patients with HCC, 17 (5%) underwent salvage LDLT, with 5 having undergone prior major liver resection and 12 prior minor resection.
  • Recipient operation time was not prolonged in patients undergoing salvage LDLT, but bleeding complications occurred more frequently than in patients undergoing primary LDLT.
  • Overall survival rates after salvage LDLT were similar to those after primary LDLT, especially when the extent of recurrent tumor was within the Milan criteria.
  • These results indicate that every combination of prior hepatectomy and living donor liver graft is feasible for patients undergoing salvage LDLT, and the acceptable extent of HCC for salvage LDLT is equivalent to that for primary LDLT.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation. Living Donors. Salvage Therapy
  • [MeSH-minor] Adult. Feasibility Studies. Female. Hemorrhage / etiology. Humans. Male. Middle Aged. Postoperative Complications. Reoperation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2007 May;13(5):636-8 [17457856.001]
  • (PMID = 17457860.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Yamashita K, Kamiyama T, Matsushita M, Todo S: Living-donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg; 2006;13(5):393-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living-donor liver transplantation for hepatocellular carcinoma.
  • Transplant surgeons have long dreamed of achieving a complete cure for hepatocellular carcinoma (HCC) by replacing the liver with a new graft.
  • Although the early results of liver transplantation for HCC were disappointing, with 5-year survival less than 40%, improved results in patients who met the so-called Milan criteria rekindled the enthusiasm for the treatment of HCC with liver transplantation.
  • Furthermore, the recent development of living-donor liver transplantation in adults has allowed timely grafting for HCC patients and tentative expansion of the criteria for transplant candidacy in patients with HCC - although such expansion is fraught with controversy.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation. Living Donors
  • [MeSH-minor] Adult. Humans. Japan. United States


59. Xuan SY, Li N, Shi YX, Sun Y, Zhang J, Jiang WJ, Qiang X: [Association between Helicobacter infection in liver tissue and primary liver carcinoma]. Zhonghua Yi Xue Za Zhi; 2005 Feb 16;85(6):391-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between Helicobacter infection in liver tissue and primary liver carcinoma].
  • OBJECTIVE: To investigate the relationship between Helicobacter species and primary liver carcinoma (PLC).
  • METHODS: The liver samples resected during operation from 21 patients with PLC diagnosed by histopathology and 12 patients with other liver diseases as controls were studied.
  • Helicobacter species in liver specimens from the studied subjects were examined by PCR with Helicobacter specific 16SrRNA primers.
  • Qualitative and quantitative studies were used to assess the correlation of liver tissue helicobacter infection with PLC.
  • CONCLUSION: Helicobacter infection may exist in the liver tissues of PLC patients with a high infection rate, suggesting an association between Helicobacter infection and PLC.
  • [MeSH-major] Carcinoma, Hepatocellular / microbiology. Helicobacter. Helicobacter Infections. Liver / microbiology. Liver Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. RNA, Bacterial / analysis. RNA, Ribosomal, 16S / analysis. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854528.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


60. Yan LN, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY, Xu MQ, Ma YK, Chen ZY, Liu JW, Wu H: [Adult-to-adult living donor liver transplantation using right lobe graft: report of 24 cases]. Zhonghua Yi Xue Za Zhi; 2006 Feb 14;86(6):411-5
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-to-adult living donor liver transplantation using right lobe graft: report of 24 cases].
  • OBJECTIVE: To investigate the safety and feasibility of adult-to-adult living donor liver transplantation (A-A LDLT) using right lobe graft.
  • METHODS: From January 2005 to December 2005, 24 patients, 22 males and 2 females, aged 20 - 53, with the underlying diseases of liver cirrhosis, hepatocellular carcinoma, and Budd-Chiari syndrome, underwent A-A LDLT using right lobe graft.
  • [MeSH-major] Liver Transplantation / methods. Living Donors
  • [MeSH-minor] Adult. Budd-Chiari Syndrome / surgery. Carcinoma, Hepatocellular / surgery. Female. Hepatic Veins / surgery. Humans. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Male. Middle Aged. Treatment Outcome. Vascular Surgical Procedures

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16677554.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Li SY, An P, Cai HY, Bai X, Zhang YN, Yu B, Zuo FY, Chen G: Proteomic analysis of differentially expressed proteins involving in liver metastasis of human colorectal carcinoma. Hepatobiliary Pancreat Dis Int; 2010 Apr;9(2):149-53
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of differentially expressed proteins involving in liver metastasis of human colorectal carcinoma.
  • BACKGROUND: Early diagnosis of liver metastasis of colorectal carcinoma is very important for the appropriate treatment of such patients.
  • The present study aimed to investigate the differential expression of proteins in patients with liver metastasis of colorectal carcinomas using proteomic analysis and evaluate its potentiality in clinical diagnosis.
  • METHODS: Fluorescence two-dimensional differential in-gel electrophoresis (2-D DIGE) was used to analyze and compare the protein expression between normal mucosa, the primary focus, and liver metastases.
  • Immunohistological staining was used to confirm the expression of differentially expressed proteins in colorectal carcinomas and areas of liver metastasis.
  • In 20 differentially expressed proteins, 3 were down-regulated and 17 up-regulated in liver metastases.
  • Proteomic analysis showed that the S-adenosylmethionine transgelin variant was down-regulated in liver metastasis tissues.
  • Zinc finger protein 64 homolog (Zfp64), guanine nucleotide exchange factor 4 (GEF4), human arginase, glutathione S-transferases (GSTs) A3, and tumor necrosis factor alpha (TNF-alpha)-induced protein 9 were up-regulated in liver metastasis tissues.
  • Immunohistochemical staining confirmed that human arginase expression was higher in liver metastases than in the primary focus.
  • CONCLUSIONS: There was a significant difference in protein expression between the primary focus of colorectal carcinoma and liver metastases.
  • The differentially regulated proteins were closely related to liver metastasis of colorectal carcinoma.
  • Elevated human arginase may be an important molecular marker for liver metastasis from colorectal carcinoma.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Neoplasm Proteins / analysis. Proteomics
  • [MeSH-minor] Adult. Aged. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry. Male. Mass Spectrometry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382585.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


62. Izumi Y, Hiramatsu N, Itose I, Inoue T, Sasagawa A, Egawa S, Nishida T, Kakiuchi Y, Toyama T, Nakanishi F, Ohkawa K, Mochizuki K, Kanto T, Tsujii M, Takehara T, Tsuji S, Kato M, Kasahara A, Hayashi N: Juvenile hepatocellular carcinoma with congestive liver cirrhosis. J Gastroenterol; 2005 Feb;40(2):204-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile hepatocellular carcinoma with congestive liver cirrhosis.
  • A case of juvenile hepatocellular carcinoma (HCC) with congestive liver cirrhosis is reported.
  • Computed tomography showed four space-occupying lesions in the liver; 45 mm, 20 mm, 12 mm, and 10 mm in size.
  • Histology of the cancerous and the noncancerous liver tissue revealed HCC, moderately differentiated type, in cirrhotic liver with congestion.
  • This patient had no background factors of liver disease, except for liver congestion, associated with the chronic heart failure.
  • Because most patients with cardiac cirrhosis die of cardiac disease, only a small number of these patients develop liver failure.
  • However, the incidence of HCC in patients with congestive liver disease is likely to increase in the future, as survival time is prolonged with the advances in treatment for chronic heart failure.
  • Therefore, patients with congestive liver disease should be followed, taking into account the possibility of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Cirrhosis / complications. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Cardiomegaly / etiology. Cardiomegaly / radiography. Diaphragm / pathology. Dilatation, Pathologic. Female. Heart Failure / complications. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770406.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Yoon YS, Han HS, Cho JY, Ahn KS: Total laparoscopic liver resection for hepatocellular carcinoma located in all segments of the liver. Surg Endosc; 2010 Jul;24(7):1630-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic liver resection for hepatocellular carcinoma located in all segments of the liver.
  • BACKGROUND: Laparoscopic liver resection (LLR) is still not a well-established treatment modality for hepatocellular carcinoma (HCC).
  • CONCLUSIONS: Our experience shows that LLR can be safely performed in selected patients with HCC located in all segments of the liver, including the posterosuperior segments, with acceptable postoperative morbidity and oncologic results.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Laparoscopy. Liver / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035349.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M: Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell; 2007 Feb;11(2):119-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.
  • The function of NEMO in the adult liver remains elusive.
  • Here we show that ablation of NEMO in liver parenchymal cells caused the spontaneous development of hepatocellular carcinoma in mice.
  • Tumor development was preceded by chronic liver disease resembling human nonalcoholic steatohepatitis (NASH).
  • These results reveal that NEMO-mediated NF-kappaB activation in hepatocytes has an essential physiological function to prevent the spontaneous development of steatohepatitis and hepatocellular carcinoma, identifying NEMO as a tumor suppressor in the liver.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Fatty Liver / etiology. I-kappa B Kinase / physiology. Intracellular Signaling Peptides and Proteins / physiology. Liver Neoplasms / etiology
  • [MeSH-minor] Animals. Apoptosis. Bromodeoxyuridine. Cells, Cultured. Electrophoretic Mobility Shift Assay. Fas-Associated Death Domain Protein / genetics. Fas-Associated Death Domain Protein / physiology. Female. Fibroblasts / cytology. Fibroblasts / metabolism. Gene Expression. Hepatocytes / metabolism. Immunoblotting. In Situ Nick-End Labeling. Leucine Zippers. Liver / injuries. Liver / metabolism. Liver / pathology. Male. Mice. Mice, Knockout. Mice, Transgenic. NF-kappa B / genetics. NF-kappa B / metabolism. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Ubiquitin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Cell. 2007 Feb;11(2):99-101 [17292819.001]
  • (PMID = 17292824.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fas-Associated Death Domain Protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / NEMO protein, mouse; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Ubiquitin; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.10 / Ikbkb protein, mouse; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


65. Klein WM, Molmenti EP, Colombani PM, Grover DS, Schwarz KB, Boitnott J, Torbenson MS: Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol; 2005 Oct;124(4):512-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver carcinoma arising in people younger than 30 years.
  • Primary liver carcinomas in children and young adults are uncommon and poorly described.
  • We examined primary liver carcinomas in people younger than 30 years and performed immunostains for markers of biliary (cytokeratin [CK] 7, CK19, CD56) and hepatocellular (HepPar) differentiation.
  • We found 23 primary liver carcinomas were found: 13 hepatocellular carcinomas (HCCs), 9 fibrolamellar carcinomas (FLCs), and 1 cholangiocarcinoma.
  • In contrast, a control group of 65 adult HCCs showed less CK7 positivity (24 [37%]; P = .03).
  • No chronic background liver disease was seen, although 3 cases showed foci of altered hepatocytes.
  • HCCs are the most common primary liver carcinoma in children and young adults followed by FLCs.
  • They are morphologically similar to adult HCC, but more likely to be CK7(+).
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Animals. Antigens, CD56 / analysis. Bile Duct Neoplasms / chemistry. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / chemistry. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Immunohistochemistry / methods. Keratin-7. Keratins / analysis. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2005 Oct;124(4):491-3 [16146817.001]
  • (PMID = 16146811.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


66. Haberal M, Emiroglu R, Karakayali H, Moray G, Yilmaz U, Ozçay F, Bilezikci B, Arslan G: Expanded criteria for hepatocellular carcinoma and liver transplantation. Int Surg; 2007 Mar-Apr;92(2):110-5
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expanded criteria for hepatocellular carcinoma and liver transplantation.
  • In this study, we evaluated our early results of liver transplantation for hepatocellular carcinoma.
  • Between January 2003 and June 2006, 26 patients (4 women and 22 men; age, 1.1-65 years) with preoperatively diagnosed or incidental hepatocellular carcinoma (HCC) underwent liver transplantation at our center.
  • There has been only one tumor recurrence that was 4 months after liver transplantation.
  • Liver transplantation provides long patient and disease-free survival, even in patients with HCC that exceeds the Milan criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Hepatectomy. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Patient Selection. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17518254.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Mittler J, Pascher A, Jonas S, Pratschke J, Neumann UP, Langrehr JM, Neuhaus P: Adult living donor liver transplantation: living donation of the right liver lobe. Langenbecks Arch Surg; 2007 Nov;392(6):657-62
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult living donor liver transplantation: living donation of the right liver lobe.
  • BACKGROUND: Adult living donor liver transplantation (LDLT) has become a routine treatment option for patients waiting for liver transplantation.
  • In European and North American countries, LDLT for adult recipients is mainly performed with right lobe grafts.
  • Indications, when compared to deceased donor liver transplantation, are controversial.
  • MATERIALS AND METHODS: In our institution, patients suffering from hepatocellular carcinoma in cirrhosis, non-resectable hilar cholangiocarcinoma, viral hepatitis associated cirrhosis, as well as cholestatic liver and biliary disease are considered good candidates for LDLT.
  • CONCLUSION: Given the ongoing shortage of donor organs, adult LDLT has become a routine treatment option for patients waiting for liver transplantation.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443341.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Amarapurkar AD, Vibhav, Kim V: Angiogenesis in liver cirrhosis and hepatocellular carcinoma. Indian J Pathol Microbiol; 2008 Jul-Sep;51(3):323-8
MedlinePlus Health Information. consumer health - Cirrhosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in liver cirrhosis and hepatocellular carcinoma.
  • BACKGROUND: Angiogenesis has been well documented in hepatocellular carcinoma (HCC).
  • As liver cirrhosis is considered preneoplastic condition, the aim of this study was to evaluate the process of angiogenesis using CD 34 as an endothelial cell marker in normal liver, cirrhosis and HCC.
  • MATERIALS AND METHODS: A total of 111 cases were included in this study, which consisted of 30 cases each of normal liver and cirrhosis that were all autopsy cases.
  • Twenty-one cases of HCC included 10 autopsy specimens, nine surgically resected specimens and two liver biopsies.
  • Remaining were 30 cases of metastasis to the liver, which included 20 autopsy specimens, one surgically resected specimen and nine liver biopsies.
  • Paraffin-embedded liver sections of all these cases were stained routinely by hematoxylin-eosin stain, while immunohistochemistry for CD 34 was performed for expression of endothelial cells.
  • The positivity of CD 34 staining was evaluated by counting in 10 high-power field, grading was done from 0 to 4 and compared between normal liver, cirrhosis and HCC and metastasis.
  • RESULTS: CD 34 was positive in 16/30 (53.3%) cases of cirrhosis, 18/21 (85%) cases of HCC and 26 (86.6%) of metastasis to the liver.
  • None of the normal liver showed any positivity.
  • CONCLUSION: Over expression of endothelial cell marker CD 34 with gradual progression was found from normal liver to cirrhosis to HCC and metastasis.
  • Understanding of this process of angiogenesis might help in the design of efficient and safe antiangiogenic therapy for these liver disorders.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Cirrhosis / pathology. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / analysis. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723951.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


69. Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Maehara Y: Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg; 2008;15(2):124-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma.
  • The role of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) has evolved over the past two decades, and transplantation has become one of the few curative treatment modalities for patients with HCC.
  • (2) the effect of downstaging HCC before LT, including transarterial catheter chemoembolization (TACE) and radiofrequency ablation (RFA); and (3) living-donor versus deceased-donor liver transplantation for HCC patients.
  • Furthermore, the experience accumulated with locoregional therapies such as TACE and RFA as bridging procedures to LT, along with the reduced waiting time under the HCC-adjusted MELD (model for endstage liver disease) system for organ allocation has led to improved outcomes.
  • With the recent advances in adult living-donor liver transplantation (LDLT), there may be a marked change in the role of liver transplantation for hepatic malignancies, in particular for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation. Living Donors. Neoplasm Recurrence, Local / etiology


70. Hervieu V, Lombard-Bohas C, Dumortier J, Boillot O, Scoazec JY: Primary acinar cell carcinoma of the liver. Virchows Arch; 2008 Mar;452(3):337-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the liver.
  • We report a case of acinar cell carcinoma primary to the liver.
  • The tumor was diagnosed in a 35-year-old woman complaining of abdominal pain and asthenia; serum alpha-fetoprotein (AFP) levels were increased at 6,000 IU/mL; imaging studies showed a hypervascular mass located in the left lobe of the liver.
  • The final diagnosis, based on histological, immunohistochemical, and ultrastructural arguments, was extra-pancreatic acinar cell carcinoma, primary to the liver.
  • This unusual lesion is likely to be the result of an abnormal differentiation pathway involving a transformed multipotential progenitor cell.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Liver / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Treatment Outcome. alpha 1-Antitrypsin / analysis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193278.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / alpha 1-Antitrypsin; 0 / alpha-Fetoproteins
  •  go-up   go-down


71. Dalgic A, Karakayali H, Moray G, Emiroglu R, Sozen H, Torgay A, Haberal M: Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria. Transplant Proc; 2005 Sep;37(7):3154-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria.
  • Liver transplantation is the only curative treatment option for patients with cirrhosis and unresectable hepatocellular carcinoma (HCC) without extrahepatic dissemination.
  • In this study, we evaluate the early results of liver transplantation for unresectable HCC.
  • Between 2003 and 2004, 10 patients (three woman, seven men; aged 1.1 to 64 years) with occult or incidental HCC underwent liver transplantation.
  • Low-dose immunosuppression and expanded criteria for liver transplantation for HCC appear to have beneficial effects on disease recurrence and patient outcomes, especially in regard to living donation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / immunology. Tacrolimus / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Infant. Male. Middle Aged. Patient Selection. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213334.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


72. Sun K, Wu CT, Lei ST, Huang XC: [Effects of FOLFOX4 neoadjuvant chemotherapy on the non-tumoral liver in patients with metastatic colorectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May;13(5):350-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of FOLFOX4 neoadjuvant chemotherapy on the non-tumoral liver in patients with metastatic colorectal carcinoma].
  • OBJECTIVE: To investigate the effect of FOLFOX4 neoadjuvant chemotherapy on the non-tumoral liver in patients with metastatic colorectal carcinoma.
  • METHODS: A large series of surgically resected liver metastases(n=42) was selected and the morphological changes were examined by light and electron microscope.
  • RESULTS: Twelve (63.2%) of the 19 post-chemotherapy liver resection specimens had sinusoidal dilatation and hemorrhage.
  • CONCLUSION: Systemic FOLFOX4 neoadjuvant chemotherapy in metastatic colorectal carcinoma frequently causes morphological injuries involving hepatic microvasculature and induces CTGF expression in hepatic stellate cells to participate in hepatic fibrosis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499303.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


73. Xu MH, Qu Q, Zhang GY: [H.pylori in patients with cirrhosis and liver cirrhosis with hepatocellular carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Oct;32(5):917-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [H.pylori in patients with cirrhosis and liver cirrhosis with hepatocellular carcinoma].
  • OBJECTIVE: To understand the prevalence of H.pylori infection in patients with cirrhosis, and liver cirrhosis with hepatocellular carcinoma(HCC), and to investigate the relationship between H.pylori infection and liver cirrhosis, and liver cirrhosis with hepatocellular carcinoma in patients.
  • METHODS: Serum anti-H.pylori antibodies IgG (HpIgG) was measured by dot immunogold filtration assay (DIGFA) in 101 liver cirrhosis and 42 liver cirrhosis with hepatoma patients and alpha-fetopro-tei(AFP)was determined by chemiluminescence.
  • RESULTS: HpIgG seroprevalence was 42.57% (43/101) in the liver cirrhosis patients, and 69.05% (29/42) in the liver cirrhosis with the HCC patients.
  • HpIgG seropositivity in the liver cirrhosis with the HCC patients was higher than in those without HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / microbiology. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Liver Cirrhosis / microbiology. Liver Neoplasms / microbiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Bacterial / blood. Female. Humans. Male. Middle Aged. Risk Factors. Seroepidemiologic Studies. Young Adult. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007096.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / alpha-Fetoproteins
  •  go-up   go-down


74. Cillo U, Vitale A, Volk ML, Frigo AC, Grigoletto F, Brolese A, Zanus G, D'Amico F, Farinati F, Burra P, Russo F, Angeli P, D'Amico DF: The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis; 2010 Sep;42(9):642-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The survival benefit of liver transplantation in hepatocellular carcinoma patients.
  • BACKGROUND: There are no studies evaluating the survival benefit of liver transplantation over alternative therapies for patients with hepatocellular carcinoma.
  • METHODS: The short- to mid-term survival benefit (study group=135 aggressively treated patients with hepatocellular carcinoma, 52% beyond Milan criteria at pathology) was calculated by comparing the mortality rates of liver transplantation vs alternative therapies patients.
  • A Markov prediction model was then created to estimate the long-term survival benefit of liver transplantation (gain in life expectancy) over alternative therapies.
  • The long-term survival rates in the liver transplantation group were calculated using the Metroticket website calculator (http://89.96.76.14/metroticket/calculator/).
  • RESULTS: The short- to mid-term analysis indicated that liver transplantation afforded no significant survival benefit in the group of patients with hepatoma as a whole (hazard ratio=1.229, 95% confidence interval 0.544-2.773, p=.6200).
  • In the long-term analysis, the gain in life expectancy of liver transplantation vs alternative therapies was 6.115 years (base-case analysis) and the main determinants of gain in life expectancy were the 5-year survival prospects after alternative therapies and the patient's age.
  • CONCLUSIONS: The survival benefit of liver transplantation for patients with hepatocellular carcinoma is strongly related to the patient's age and the effectiveness of available alternative therapies.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Markov Chains. Middle Aged. Patient Selection. Retrospective Studies. Survival Analysis. Survivors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • [CommentIn] Dig Liver Dis. 2010 Sep;42(9):608-10 [20678743.001]
  • (PMID = 20381438.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Liu Y, Sang XT, Gao WS, Mao YL, Liu YW, Liu HF, Yang ZY, Yang SZ, Zhong SX, Huang JF: [The first case of primary epithelial-myoepithelial carcinoma in the liver]. Zhonghua Wai Ke Za Zhi; 2006 Nov 1;44(21):1477-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The first case of primary epithelial-myoepithelial carcinoma in the liver].
  • OBJECTIVE: To report the first case of primary epithelial-myoepithelial carcinoma (EMC) in the liver.
  • A 10 cm lesion was detected in the right liver upon a routine examination.
  • CONCLUSIONS: Primary EMC is difficult to be finally diagnosed prior to the surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Myoepithelioma / diagnosis
  • [MeSH-minor] Actins / analysis. Adult. Female. Hepatectomy / methods. Humans. Immunohistochemistry. Muscle, Smooth / chemistry. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Epithelial-Myoepithelial Carcinoma.
  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349174.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / S100 Proteins
  •  go-up   go-down


76. Cazejust J, De Baère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S, Baudin E: Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol; 2010 Oct;21(10):1527-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma.
  • PURPOSE: To retrospectively evaluate the effectiveness, tolerance, and predictors of response to transcatheter arterial chemoembolization for treatment of liver metastases from adrenocortical carcinoma.
  • MATERIALS AND METHODS: Twenty-nine patients with progressive liver metastases from adrenocortical carcinoma were treated with transcatheter arterial chemoembolization.
  • The size of liver metastases, percentage of liver involvement, and Lipiodol uptake were studied as potential predictive factors of response.
  • Time to liver and metastatic lesion progression were considered as endpoints.
  • RESULTS: Three months after transcatheter arterial chemoembolization, a liver morphologic response was observed in six of 29 patients (21%), stabilization in 18 (62%), and progression in five (17%).
  • CONCLUSIONS: Transcatheter arterial chemoembolization should be considered as part of the therapeutic arsenal to treat liver metastases from adrenocortical carcinoma.
  • The size of liver metastases and the percentage of Lipiodol uptake may help identify patients likely to benefit most from transcatheter arterial chemoembolization.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / secondary. Hemostatics / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Catheterization, Peripheral. Chemoembolization, Therapeutic. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20801688.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics
  •  go-up   go-down


77. Lee HS: Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: the controversies continue. Dig Dis; 2007;25(4):296-8
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: the controversies continue.
  • Liver transplantation has now become a favored option for patients with early-stage hepatocellular carcinoma (HCC) with or without impaired hepatic function as a complication of underlying cirrhosis.
  • To overcome the persistent donor organ shortage, the use of adult-to-adult living donor liver transplantation (LDLT) has recently increased, especially in Asian countries.
  • In contrast to deceased donor liver transplantation, the benefit of LDLT is better appreciated in terms of gain in life expectancy than in terms of survival when the wishes of both patient and donor outweigh the donor risk.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Liver Transplantation. Patient Selection

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17960062.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


78. Lin HT, Liu GJ, Wu D, Lou JY: Metastasis of primary gallbladder carcinoma in lymph node and liver. World J Gastroenterol; 2005 Feb 7;11(5):748-51
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of primary gallbladder carcinoma in lymph node and liver.
  • AIM: To evaluate the patterns with metastasis of gallbladder carcinoma in lymph nodes and liver.
  • The patterns with metastasis of primary gallbladder carcinoma in lymph nodes and liver were examined histopathologically and classified as TNM staging of the American Joint Committee on Cancer.
  • RESULTS: Of the 45 patients, 29 (64.4%) had a lymph node positive disease and 20 (44.4%) had a direct invasion of the liver.
  • The frequency of involvement of lymph nodes was strongly influenced by the depth of the primary tumor (P = 0.0001).
  • CONCLUSION: Complete resection of the regional lymph nodes is important in advanced primary gallbladder carcinoma (PGC).
  • The initial sites of liver spread are located mostly in segments IV and V.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystectomy. Hepatectomy. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655837.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250754
  •  go-up   go-down


79. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg; 2009 Nov;250(5):738-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.
  • BACKGROUND/PURPOSE: Liver transplantation (LT) is the best theoretical treatment of hepatocellular carcinoma (HCC) fulfilling the Milan criteria (TNM stages 1-2).
  • Liver resection (LR) may represent an alternative in these patients.
  • PATIENTS: From 1990 to 2007, 274 patients underwent liver resection for HCC.
  • Ten were TNM stage 1 and 57 stage 2 and all had chronic liver disease.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatitis / complications. Hepatitis C / complications. Humans. Liver Cirrhosis, Alcoholic / complications. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


80. Scatton O, Liddo G, Belghiti J: Liver transplantation for hepatocellular carcinoma: current topics in France. J Hepatobiliary Pancreat Sci; 2010 Sep;17(5):567-73
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma: current topics in France.
  • BACKGROUND: Excellent survival obtained with liver transplantation (LT) for limited hepatocellular carcinoma (HCC) in patients with chronic liver disease is still challenged by the increasing discrepancy between candidates and grafts available.
  • RESULTS: Although the vast majority of cirrhotic patients with HCC are transplanted within the Milan criteria; the number of candidates is continually rising, while the number of grafts available is stable with a disappearance of adult LDLTs.
  • Moreover, the new rules for organ allocations, mainly based on the MELD score, minimize the accessibility to liver grafts for patients with HCC and compensated liver disease.
  • Moreover, the use of liver resection (LR) as a bridge therapy, showing that initial resection does not impair short- and long-term survival, led French surgeons to develop the concept of LR as a way to select patients who might benefit from LT and to use it, in selected cases, as a primary therapy, considering LT as salvage treatment in case of recurrence.
  • Moreover, the country of égalité is actually modifying the rules of graft attribution in order to reduce the inequality between the HCC patients with poor and good liver function.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. France / epidemiology. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760361.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Wai CT, Lee YM, Wang SC, Da Costa M, Isaac J, Wee A, Lim SG: Liver transplantation for hepatocellular carcinoma in Singapore. Singapore Med J; 2006 Jul;47(7):584-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma in Singapore.
  • INTRODUCTION: The prognosis of patients with hepatocellular carcinoma (HCC) is poor.
  • Surgical resection offers the benefit of removal of the tumour but is associated with liver decompensation and tumour recurrence, even after successful surgery.
  • Liver transplantation offers the benefits of complete tumour removal with prevention of both decompensation and recurrence post-operation.
  • This paper aims to review results of liver transplantation for patients with HCC in Singapore.
  • METHODS: All adult patients with HCC accepted on the waiting list for liver transplantation (based on the Milan criteria) from 1996 to 2004 in Singapore were reviewed.
  • Among all patients, mortality was significantly related to baseline white cell counts, prothrombin time, age, alpha-foetoprotein level, Child-Pugh score, and whether patients underwent transplant.
  • Liver transplant is an effective treatment for patients with a HCC, with a reasonable long-term survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810428.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


82. Lee KW, Park JW, Park JB, Kim SJ, Choi SH, Heo JS, Kwon CH, Kim DJ, Han YS, Lee SK, Joh JW: Liver transplantation for hepatocellular carcinoma with bile duct thrombi. Transplant Proc; 2006 Sep;38(7):2093-4
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma with bile duct thrombi.
  • In a few cases of hepatocellular carcinoma (HCC), jaundice results from obstructive causes, including tumor invasion or thrombi in the bile duct.
  • We have reported herein our experience with liver transplantation (OLT) for HCC cares showing bile duct thrombi (BDT).
  • From September 1996 to August 2004, 140 adult patients underwent OLT for HCC at our center.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cholestasis / complications. Liver Neoplasms / surgery. Liver Transplantation / physiology
  • [MeSH-minor] Adult. Humans. Jaundice / etiology. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980009.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Moray G, Karakayali F, Yilmaz U, Ozcay F, Bilezikci B, Haberal M: Expanded criteria for hepatocellular carcinoma and liver transplantation. Transplant Proc; 2007 May;39(4):1171-4
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expanded criteria for hepatocellular carcinoma and liver transplantation.
  • In this study, we evaluated our early results of liver transplantation for hepatocellular carcinoma (HCC).
  • Between January 2004 and June 2006, 26 patients (4 females, 22 males; aged 1.1-65 years) with preoperatively diagnosed or incidental HCC underwent liver transplantation at our center.
  • There has been only 1 tumor recurrence, which occurred 4 months after liver transplantation.
  • In conclusion, liver transplantation provides long patient and disease-free survival, even in patients with HCC that exceeds the Milan criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Patient Selection. Retrospective Studies. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524923.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. El-Meteini M, Fayez A, Fathy M, Abdalaal A, Safaan H, Mostafa I, Abdalaal M, Mokhtar A, Salah M, El-Dorry A, Abdalwahab S, El-Monayeri M, Boillot O: Living related liver transplantation for hepatocellular carcinoma in Egypt. Transplant Proc; 2005 Sep;37(7):3141-3
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living related liver transplantation for hepatocellular carcinoma in Egypt.
  • BACKGROUND: Living related liver transplantation (LRLT) for hepatocellular carcinoma (HCC) in cirrhotic patients has emerged as a rewarding therapy for a cure.
  • PATIENTS AND METHODS: From October 2001 to June 2004, 47 adult patients with end-stage liver disease (ESLD) have been treated using LRLT, including 11 (9 males and 2 females) with HCC superimposed on hepatitis C virus (HCV)-related (n = 10) or hepatitis B virus-related (n = 1) cirrhosis.
  • Microvascular invasion was documented in 3 explants, 1 of which experienced HCC recurrence and the other 2 received 6 cycles of Doxorubicin following normalization of their liver profile.
  • CONCLUSION: Our current data confirm the efficacy of LRLT for treatment of HCC superimposed on liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods. Living Donors
  • [MeSH-minor] Adult. Egypt. Family. Female. Humans. Liver Failure / etiology. Liver Failure / surgery. Male. Middle Aged. Postoperative Complications / classification. Retrospective Studies. Survival Analysis


85. O'Donnell DH, Ryan R, Hayes B, Fennelly D, Gibney RG: Hepatocellular carcinoma complicating cystic fibrosis related liver disease. J Cyst Fibros; 2009 Jul;8(4):288-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma complicating cystic fibrosis related liver disease.
  • We report a patient with documented CF related liver disease for which he was under routine surveillance that presented with histologically proven hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Cystic Fibrosis / complications. Liver Cirrhosis / complications. Liver Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy. Humans. Liver / pathology. Magnetic Resonance Imaging. Male


86. Lee NP, Leung KW, Cheung N, Lam BY, Xu MZ, Sham PC, Lau GK, Poon RT, Fan ST, Luk JM: Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics; 2008 May;8(10):2136-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma.
  • To identify potential oncofetal biomarkers that distinguish hepatocellular carcinoma (HCC) from healthy liver tissues, we compared and analyzed the proteomic profiles of mouse livers at different developmental stages.
  • Fetal (E13.5, E16.5), newborn (NB), postnatal (3-week) and adult (3-month) livers were isolated and profiled by 2-D PAGE.
  • Unsupervised hierarchical tree analysis segregated the proteins into fetal, NB, and postnatal-adult clusters.
  • Fetal markers (hPCNA, hHSP7C, hHEM6) and postnatal-adult markers (hARGI1, hASSY, hBHMT, hFABPL) were selected for testing against a panel of seven human hepatocyte/HCC cell lines and 59 clinical specimens.
  • The fetal proteins were found to be overexpressed in the metastatic HCC cell lines and the tumor tissues, whereas the postnatal-adult proteins were expressed in non-tumor tissues and normal hepatocytes.
  • This "Ying-Yang" pattern, as orchestrated by distinct fetal and adult markers, is hypothesized to indicate the progressive change of the liver from a growing, less-differentiated organ into a functional metabolic center.
  • Thus, embryogenesis and tumorigenesis share certain oncofetal markers and adult "hepatic" phenotypes are lost in HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver / metabolism. Liver Neoplasms / metabolism. Proteins / analysis. Proteomics / methods
  • [MeSH-minor] Animals. Animals, Newborn. Cell Line, Tumor. Cluster Analysis. Electrophoresis, Gel, Two-Dimensional. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425728.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


87. Park JW, Lee KW, Kim SJ, Choi SH, Heo JS, Kwon CH, Kim DJ, Han YS, Lee SK, Joh JW: Outcome of patients with recurrent hepatocellular carcinoma in liver transplantation. Transplant Proc; 2006 Sep;38(7):2121-2
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with recurrent hepatocellular carcinoma in liver transplantation.
  • Liver transplantation (OLT) is the treatment of choice for patients with hepatic cirrhosis related hepatocellular carcinoma (HCC).
  • Among 156 liver transplant patients for HCC from June 1996 to February 2005, 23 had recurrent HCC.
  • The most common recurrence site was the grafted liver (n = 15), next was bone (n = 11), lung (n = 8), lymph node (n = 6), brain (n = 4), skin (n = 2), adrenal gland (n = 1).
  • There were no significant differences between the two groups in age or tumor size, number of tumors, cell differentiation, alpha-feto protein levels, tumor staging, number of patients within Milan criteria, steroid pulse therapy, infectious diseases, and immunostaining of tumor.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Neoplasm Staging. Recurrence. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980018.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Karakayali H, Moray G, Sozen H, Dalgic A, Emiroglu R, Haberal M: Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc; 2006 Mar;38(2):575-8
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expanded criteria for liver transplantation in patients with hepatocellular carcinoma.
  • INTRODUCTION: Liver transplantation is the only curative treatment for patients with cirrhosis and unresectable hepatocellular carcinoma (HCC) without extrahepatic dissemination.
  • Since criteria for transplantation in HCC are controversial, we evaluated our early results of liver transplantation for unresectable HCC.
  • MATERIALS AND METHODS: Three women and 14 men (age range, 1.1 to 64 years) with preoperatively diagnosed or incidentally discovered HCC underwent liver transplantation.
  • DISCUSSION: Low-dose immunosuppressive therapy and expanded criteria for liver transplantation in patients with HCC, especially when donation from a living related donor is possible, appear to inhibit disease recurrence and improve outcomes.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Cadaver. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Living Donors. Male. Middle Aged. Patient Selection. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549179.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Liu XD, Yang ZY, Wang SG, Bie P, Zheng SG, Zhang LD, He Y, Lu Q, Yang ZQ, Dong JH: [Liver transplantation for treating hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi; 2006 Apr;14(4):255-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation for treating hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the role of orthotopic liver transplantation (OLT) in treating hepatocellular carcinoma (HCC).
  • METHODS: Data of 92 consecutive orthotopic liver transplantations (OLTs) performed during January 1999 and February 2005 at our institution were analyzed.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635291.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC: Liver transplantation in hepatocellular carcinoma. Transpl Int; 2005 Mar;18(3):278-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in hepatocellular carcinoma.
  • Liver transplantation is one option of surgical treatment for cirrhotic patients with hepatocellular carcinoma, it not only treats the malignancy but also the underlying disease.
  • The development of adult living donor liver transplantation has proved to be a good alternative in this type of patients even if they do not fulfill the conventional criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730486.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


91. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK: Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol; 2010 Aug;40(8):768-73
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
  • OBJECTIVE: Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials.
  • The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined.
  • METHODS: We retrospectively analyzed 13 patients who were treated with sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
  • RESULTS: The median time to recurrence from liver transplantation was 12.3 months (95% confidence interval: 8.5-16.1 months).
  • CONCLUSIONS: These findings suggest that sorafenib may be a feasible treatment option regarding its efficacy and safety for recurrent hepatocellular carcinoma after liver transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Disease Progression. Drug Eruptions / etiology. Female. Hematologic Diseases / chemically induced. Humans. Liver Transplantation. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494947.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


92. Chen HY, Juan CC, Ker CG: Laparoscopic liver surgery for patients with hepatocellular carcinoma. Ann Surg Oncol; 2008 Mar;15(3):800-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic liver surgery for patients with hepatocellular carcinoma.
  • BACKGROUND: Laparoscopic hepatectomy is feasible for hepatocellular carcinoma (HCC) today.
  • This is a retrospective study of the patients with HCC treated by liver resection with a totally laparoscopic approach.
  • METHODS: This study recruited 116 patients (92 male, 24 female) that underwent laparoscopic liver resection (LR) for HCC.
  • CONCLUSION: Laparoscopic liver resection is a procedure of significant risk and is more technically demanding in comparison with traditional open method.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165879.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'eng FK: Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg; 2005 Mar;92(3):348-55
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for hepatocellular carcinoma in patients with cirrhosis.
  • BACKGROUND: Although liver resection is now a safe procedure, its role for hepatocellular carcinoma (HCC) in patients with cirrhosis remains controversial.
  • METHODS: This study compared the results of liver resection for HCC in patients with cirrhosis over two time intervals.
  • Early and long-term results after liver resection in the two periods were compared, and clinicopathological characteristics that influenced survival were identified.
  • CONCLUSION: The results of liver resection for HCC in patients with cirrhosis improved over time.
  • Liver resection remains a good treatment option in selected patients with HCC arising from a cirrhotic liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Postoperative Care / methods. Preoperative Care / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd.
  • (PMID = 15672423.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Ohwada S, Izumi M, Tanahashi Y, Kawate S, Hamada K, Tsutsumi H, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Combined liver and inferior vena cava resection for adrenocortical carcinoma. Surg Today; 2007;37(4):291-7
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver and inferior vena cava resection for adrenocortical carcinoma.
  • PURPOSE: Adrenocortical carcinoma (ACC) is a rare malignancy, usually diagnosed at an advanced stage when it has invaded or adhered to adjacent organs.
  • We report our experience of performing combined liver and inferior vena cava (IVC) resection for ACC.
  • METHODS: Six patients with clinical stage III (n = 4) or IV (n = 2) ACC underwent combined resection of the liver and IVC.
  • RESULTS: Perioperative mortality was zero, and morbidity was 33.3%, with temporary liver failure in two patients and renal failure in one patient.
  • CONCLUSIONS: Patients with ACC involving both the liver and IVC are candidates for partial hepatectomy and segmental IVC resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / secondary. Adrenocortical Carcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis Implantation. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Polytetrafluoroethylene. Survival Rate

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387560.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


95. Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL: Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg; 2006 Apr;243(4):499-506
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives.
  • OBJECTIVE: Report the midterm results of laparoscopic resection for hepatocellular in chronic liver disease (CLD).
  • SUMMARY BACKGROUND DATA: Surgical resection for hepatocellular carcinoma (HCC) in chronic liver disease (CLD) remains controversial because of high morbidity and recurrence rates.
  • Laparoscopic resection of liver tumors has recently been developed and could reduce morbidity.
  • METHODS: From 1998 to 2003, patients with HCC and CLD were considered for laparoscopic liver resection.
  • Inclusion criteria were chronic hepatitis or Child's A cirrhosis, solitary tumor < or =5 cm in size, and location in peripheral segments of the liver.
  • Liver resections included anatomic resection in 17 cases and non anatomic resection in 10.
  • Treatment of recurrence was possible in 4 patients (50%), including orthotopic liver transplantation, right hepatectomy, radiofrequency ablation, and chemoembolization in 1 case each.
  • CONCLUSION: Our study shows that laparoscopic liver resection for HCC in selected patients is a safe procedure with very good midterm results.
  • This approach could have an impact on the therapeutic strategy of HCC complicating CLD as a treatment with curative intent or as a bridge to liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Feasibility Studies. Female. Hepatitis, Chronic / epidemiology. Humans. Laparoscopy. Liver Cirrhosis / epidemiology. Liver Transplantation. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):373-82 [11882759.001]
  • [Cites] Surgery. 2002 Mar;131(3):311-7 [11894036.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Liver Transpl. 2002 Oct;8(10):873-83 [12360427.001]
  • [Cites] Ann Intern Med. 2003 Feb 18;138(4):299-306 [12585827.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):236-42 [12595052.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):923-9 [12648972.001]
  • [Cites] Liver Transpl. 2003 May;9(5):513-20 [12740796.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):29-34 [12832962.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):763-9; discussion 769 [12860758.001]
  • [Cites] Arch Surg. 2003 Nov;138(11):1207-13 [14609868.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):150-9 [14745321.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S86-90 [14762846.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):753-62 [11088070.001]
  • [Cites] Eur Radiol. 2001;11(6):914-21 [11419162.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):707-13 [11584366.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10):1294-300 [15376311.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1521-31 [15470215.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):900-9 [15492574.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S261-7 [15508092.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):114-7 [1714267.001]
  • [Cites] Hepatology. 1994 Jul;20(1 Pt 1):15-20 [8020885.001]
  • [Cites] Surgery. 1996 Jan;119(1):40-5 [8560384.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):330-3 [8665183.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1142-3 [9343506.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):214-5 [9449893.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):460-6 [10203077.001]
  • [Cites] Radiology. 1999 Mar;210(3):655-61 [10207464.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • (PMID = 16552201.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448957
  •  go-up   go-down


96. Zhou LX, Yan LN: [Prognostic factors of hepatocellular carcinoma after liver transplantation]. Ai Zheng; 2006 Jun;25(6):736-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of hepatocellular carcinoma after liver transplantation].
  • BACKGROUND & OBJECTIVE: Liver transplantation (LT) is the best treatment for hepatocellular carcinoma (HCC), however, prognostic factors and selection of patients with HCC for LT are controversial.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation. Neoplastic Cells, Circulating / pathology. Portal Vein
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764771.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


97. Urahashi T, Lynch SV, Kim YH, Balderson GA, Fawcett JW, Crawford DH, Strong RW: Undetected hepatocellular carcinoma in patients undergoing liver transplantation: is associated with favorable outcome. Hepatogastroenterology; 2007 Jun;54(76):1192-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undetected hepatocellular carcinoma in patients undergoing liver transplantation: is associated with favorable outcome.
  • BACKGROUND/AIMS: The aim of the study was to define the clinical characteristics and outcome of patients found to have undetected hepatocellular carcinomas (HCC) at liver transplantation.
  • Patients who underwent liver transplantation and were unexpectedly found to have a HCC despite prior workup showing normal alpha-fetoprotein levels and/or no visible radiological lesion were defined as having an undetected HCC.
  • METHODOLOGY: Thirty-two of these patients had a histological diagnosis of HCC in the explanted liver.
  • Undetected HCC was defined as a carcinoma found only on pathological evaluation of the explanted liver, with a pre-OLT workup showing a normal serum alpha-fetoprotein (AFP) level (<20 ng/mL) and/or no suspicious lesion on preoperative radiological evaluation.
  • Statistical analysis showed significant differences between undetected and detected HCCs when causes of pretransplantation liver disease, peak AFP level, tumor size, number of tumors, presence of vascular invasion or pathological differentiation were compared.
  • Undetected HCCs were associated with a better survival rate after liver transplantation (p = 0.008).
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Cirrhosis / surgery. Liver Neoplasms / diagnosis. Liver Transplantation / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome


98. Kemmer N, Neff G, Secic M, Zacharias V, Kaiser T, Buell J: Ethnic differences in hepatocellular carcinoma: implications for liver transplantation. Dig Dis Sci; 2008 Feb;53(2):551-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic differences in hepatocellular carcinoma: implications for liver transplantation.
  • Liver transplantation (LT) as a treatment for Hepatocellular Carcinoma (HCC) provides excellent outcomes if restricted to patients who meet the Milan criteria (MC).
  • Age, gender, severity of liver disease or insurance status was not predictive of meeting MC at diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / ethnology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. African Americans / statistics & numerical data. Aged. European Continental Ancestry Group / statistics & numerical data. Female. Humans. Liver Transplantation. Male. Middle Aged. Ohio / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562173.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Arista-Nasr J, Fernández-Amador JA, Martínez-Benítez B, de Anda-González J, Bornstein-Quevedo L: Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma. Ann Hepatol; 2010 Apr-Jun;9(2):186-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma.
  • Certain neuroendocrine tumors (NET) metastasized to the liver can resemble hepatocellular carcinoma (HCC) in cytological needle biopsy.
  • From a total of 285 needle biopsies with primary or metastasized hepatic neoplasms, seven cases were selected originally diagnosed as HCC or HCC vs. NET metastasized to the liver.
  • Fourteen needle biopsies of hepatocellular carcinomas were also studied for comparative purposes.
  • In all of these neoplasms the diagnosis of endocrine tumor was confirmed by immunohistochemical studies and the following information was recorded: age, sex, radiological alterations, primary site of the NET, and follow-up.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / secondary. Neuroendocrine Tumors / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mexico. Middle Aged. Predictive Value of Tests. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526014.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


100. Sotiropoulos GC, Drühe N, Sgourakis G, Molmenti EP, Beckebaum S, Baba HA, Antoch G, Hilgard P, Radtke A, Saner FH, Nadalin S, Paul A, Malagó M, Broelsch CE, Lang H: Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci; 2009 Oct;54(10):2264-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?
  • The aim of the study was to evaluate our institutional experience with monotherapies for hepatocellular carcinoma (HCC) in the setting of cirrhosis.
  • A retrospective cohort study was carried out at the tertiary care academic referral center and involved 185 consecutive HCC patients with cirrhosis and no previous treatment who underwent resection (n = 61), transarterial chemoembolization (TACE) (n = 64), or liver transplantation (LT) (n = 60).
  • Considering the scarcity of available organs, liver resection remains the best alternative option.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Hepatectomy. Liver Cirrhosis / complications. Liver Neoplasms / therapy. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Hepatic Artery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Retrospective Studies. Treatment Outcome






Advertisement